EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050120-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01925
Sample name: Paracetamol Tablets IP 650 mg
Sample appearance: White oval shaped biconvex uncoated tablets, scored on one side and plain on other side
Sample quantity: 45 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 1 | Medicine: Acetaminophen | Source: JAUSH | Batch No: PRT2501-160M | Exp : Dec.26

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 16/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		850.7	mg	-	-
4	Uniformity of weight		-2.5 to + 1.8	%	-	± 5.0
5	Dissolution		92.5 to 98.7	%	650 mg	Q. Not less than 80
6	Related Substances					
	4-aminophenol	IP-2022	Not detected	%	650 mg	Not more than 0.1
	4-chloroacetanilide		Not detected	ppm		Not more than 10
	Any other secondary Impurities		Not detected	%		Not more than 0.25
7	Assay: Each uncoated tablet contains					
	Paracetamol	IP- 2022	642.6 mg (i.e. 98.9 %)	mg	650 mg	617.5 mg to 682.5 mg (i.e. 95.0 % to 105.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050121-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01926
Sample name: Bicocetamol -650 (Paracetamol Tablets IP)
Sample appearance: White oval shaped biconvex uncoated tablets, scored on one side and plain on other side
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 2 | Medicine: Acetaminophen | Source: GENERIC | Batch No: SPAC25022 | Exp : Feb.27

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 16/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		765.9	mg	-	-
4	Uniformity of weight		-2.1 to + 1.5	%	-	± 5.0
5	Dissolution		95.6 to 97.6	%	650 mg	Q. Not less than 80
6	Related Substances					
	4-aminophenol	IP-2022	Not detected	%	650 mg	Not more than 0.1
	4-chloroacetanilide		Not detected	ppm		Not more than 10
	Any other secondary Impurities		Not detected	%		Not more than 0.25
7	Assay: Each uncoated tablet contains					
	Paracetamol	IP-2022	643.6 mg (i.e. 99.0 %)	mg	650 mg	617.5 mg to 682.5 mg (i.e. 95.0 % to 105.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01927
Sample name: Paracetamol Tablets IP
Sample appearance: White oval shaped biconvex uncoated tablets, scored on one side and plain on other side
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 3 | Medicine: Acetaminophen | Source: DAVA | Batch No: BHK05AAA | Exp : Apr.28

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 16/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		774.4	mg	-	-
4	Uniformity of weight		-1.9 to + 2.2	%	-	± 5.0
5	Dissolution		96.1 to 98.2	%	650 mg	Q. Not less than 80
6	Related Substances					
	4-aminophenol	IP-2022	Not detected	%	650 mg	Not more than 0.1
	4-chloroacetanilide		Not detected	ppm		Not more than 10
	Any other secondary Impurities		Not detected	%		Not more than 0.25
7	Assay: Each uncoated tablet contains					
	Paracetamol	IP-2022	641.9 mg (i.e. 98.8 %)	mg	650 mg	617.5 mg to 682.5 mg (i.e. 95.0 % to 105.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050123-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01928
Sample name: Paracip-650 (Paracetamol Tablets IP 650 mg)
Sample appearance: White oval shaped biconvex uncoated tablets, scored on one side and plain on other side
Sample quantity: 45 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 4 | Medicine: Acetaminophen | Source: BGENERIC | Batch No: ICHT4118 | Exp : Aug.27

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 16/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		742.8	mg	-	-
4	Uniformity of weight		-2.2 to + 1.7	%	-	± 5.0
5	Dissolution		97.3 to 99.1	%	650 mg	Q. Not less than 80
6	Related Substances					
	4-aminophenol	IP-2022	Not detected	%	650 mg	Not more than 0.1
	4-chloroacetanilide		Not detected	ppm		Not more than 10
	Any other secondary Impurities		Not detected	%		Not more than 0.25
7	Assay: Each uncoated tablet contains					
	Paracetamol	IP-2022	646.2 mg (i.e. 99.4 %)	mg	650 mg	617.5 mg to 682.5 mg (i.e. 95.0 % to 105.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050124-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01929
Sample name: Dolo-650 (Paracetamol Tablets IP)
Sample appearance: White oval shaped biconvex uncoated tablets, scored on one side and having “DOLO 650” on other side
Sample quantity: 45 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No: 5 | Medicine: Acetaminophen | Source: BRAND | Batch No: DOBS4092 | Exp: May.29

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 16/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		824.9	mg	-	-
4	Uniformity of weight		-1.2 to + 1.6	%	-	± 5.0
5	Dissolution		97.5 to 99.6	%	650 mg	Q. Not less than 80
6	Related Substances					
	4-aminophenol	IP-2022	Not detected	%	650 mg	Not more than 0.1
	4-chloroacetanilide		Not detected	ppm		Not more than 10
	Any other secondary Impurities		Not detected	%		Not more than 0.25
7	Assay: Each uncoated tablet contains					
	Paracetamol	IP-2022	647.5 mg (i.e. 99.6 %)	mg	650 mg	617.5 mg to 682.5 mg (i.e. 95.0 % to 105.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050125-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01930

Sample name: Calpol-650 (Paracetamol Tablets IP 650 mg)

Sample appearance: White elongated shaped biconvex uncoated tablet having inscribed “Calpol” on one side and “650 +” on other side

Sample quantity: 45 Nos

Condition on receipt: Good

Sample packing: Sealed Pack

Environmental condition: Not Applicable

Customer provided details: S.R No : 6 | Medicine: Acetaminophen | Source: BRAND | Batch No: EC25203 | Exp : Sep.27

Sample receipt date: 12/12/2025

Analysed between: 12/12/2025 to 16/12/2025

Sampling details: Not Sampled by Eureka

Sample seal no.: Not Applicable

Sampling procedure: Not Applicable

Sampling date: Not Applicable

Sampling location: Not Applicable

Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		860.1	mg	-	-
4	Uniformity of weight		-1.5 to + 1.9	%	-	± 5.0
5	Dissolution		96.7 to 99.4	%	650 mg	Q. Not less than 80
6	Related Substances					
	4-aminophenol	IP-2022	Not detected	%	650 mg	Not more than 0.1
	4-chloroacetanilide		Not detected	ppm		Not more than 10
	Any other secondary Impurities		Not detected	%		Not more than 0.25
7	Assay: Each uncoated tablet contains					
	Paracetamol	IP-2022	645.8 mg (i.e. 99.4 %)	mg	650 mg	617.5 mg to 682.5 mg (i.e. 95.0 % to 105.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050126-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01931
Sample name: Azithromycin Tablets IP 500 mg
Sample appearance: White elongated biconvex film coated tablet, scored on one side and plain on other side
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 7 | Medicine: Azithromycin | Source: JAUSH | Batch No: AMA250109 | Exp : Dec.26

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 22/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP-2022	Complies	-	-	-
3	Average weight		703.5	mg	-	-
4	Uniformity of weight		-2.7 to + 1.3	%	-	± 5.0
5	Dissolution		84.6 to 89.4	%	500 mg	Q. Not less than 75
6	Related Substances					
	Azithromycin impurity B	IP-2022	Not detected	%	500 mg	Not more than 2.0
	Total other secondary Impurities		Not detected	%		Not more than 3.0
7	Assay: Each film coated tablet contains					
	Azithromycin (as Dihydrate) Eq. to Anhydrous Azithromycin	IP-2022	482.6 mg (i.e. 96.5 %)	mg	500 mg	450.0 mg to 550.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050127-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01932
Sample name: Azithromycin Tablets IP 500 mg
Sample appearance: White elongated biconvex film coated tablet, scored on one side and plain on other side
Sample quantity: 32 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 8 | Medicine: Azithromycin | Source: GENADH | Batch No: 169AE13 | Exp : Nov.26

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 22/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP-2022	Complies	-	-	-
3	Average weight		623.6	mg	-	-
4	Uniformity of weight		-1.9 to + 1.2	%	-	± 5.0
5	Dissolution		86.3 to 91.7	%	500 mg	Q. Not less than 75
6	Related Substances					
	Azithromycin impurity B	IP-2022	Not detected	%	500 mg	Not more than 2.0
	Total other secondary Impurities		Not detected	%		Not more than 3.0
7	Assay: Each film coated tablet contains					
	Azithromycin Eq. to Anhydrous Azithromycin	IP-2022	485.8 mg (i.e. 97.2 %)	mg	500 mg	450.0 mg to 550.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050128-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01933
Sample name: Azithromycin Tablets IP 500 mg
Sample appearance: White elongated biconvex film coated tablet, scored on one side and plain on other side
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 9 | Medicine: Azithromycin | Source: DAVA | Batch No: T6281 | Exp : Sep.26

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 22/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP-2022	Complies	-	-	-
3	Average weight		718.2	mg	-	-
4	Uniformity of weight		-1.2 to + 1.9	%	-	± 5.0
5	Dissolution		87.8 to 91.6	%	500 mg	Q. Not less than 75
6	Related Substances					
	Azithromycin impurity B	IP-2022	Not detected	%	500 mg	Not more than 2.0
	Total other secondary Impurities		Not detected	%		Not more than 3.0
7	Assay: Each film coated tablet contains					
	Azithromycin Dihydrate Eq. to Azithromycin (Anhydrous)	IP-2022	486.2 mg (i.e. 97.2 %)	mg	500 mg	450.0 mg to 550.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050129-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01934
Sample name: AZAX-500 (Azithromycin Tablets IP 500 mg)
Sample appearance: Yellow coloured elongated biconvex film coated tablet, scored on one side and plain on other side
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 22/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

Customer provided details: S.R No : 10 | Medicine: Azithromycin | Source: BGENERIC | Batch No: MWC0036 | Exp : May.25

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP-2022	Complies	-	-	-
3	Average weight		689.1	mg	-	-
4	Uniformity of weight		-1.1 to + 1.4	%	-	± 5.0
5	Dissolution		93.7 to 101.2	%	500 mg	Q. Not less than 75
6	Related Substances					
	Azithromycin impurity B	IP-2022	Not detected	%	500 mg	Not more than 2.0
	Total other secondary Impurities		Not detected	%		Not more than 3.0
7	Assay: Each film coated tablet contains					
	Azithromycin as Dihydrate equivalent to Azithromycin (Anhydrous)	IP-2022	503.8 mg (i.e. 100.8 %)	mg	500 mg	450.0 mg to 550.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050130-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01935
Sample name: Azipro 500 Tablets(Azithromycin Tablets IP 500mg)
Sample appearance: White elongated biconvex film coated tablet, scored on one side and plain on other side
Sample quantity: 39 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 11 | Medicine: Azithromycin | Source: BGENERIC | Batch No: 4070129 | Exp : Aug.27

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 22/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP-2022	Complies	-	-	-
3	Average weight		658.7	mg	-	-
4	Uniformity of weight		-2.3 to + 1.9	%	-	± 5.0
5	Dissolution		94.8 to 102.1	%	500 mg	Q. Not less than 75
6	Related Substances					
	Azithromycin impurity B	IP-2022	Not detected	%	500 mg	Not more than 2.0
	Total other secondary Impurities		Not detected	%		Not more than 3.0
7	Assay: Each film coated tablet contains					
	Azithromycin as Dihydrate Eq. to Azithromycin (Anhydrous)	IP-2022	504.5 mg (i.e. 100.9 %)	mg	500 mg	450.0 mg to 550.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050131-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01936
Sample name: AZEE-500 (Azithromycin Tablets IP 500 mg)
Sample appearance: White elongated biconvex film coated tablet, scored on one side and plain on other side
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 12 | Medicine: Azithromycin | Source: BRAND | Batch No: 5SN0224 | Exp : Dec.27

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 22/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP-2022	Complies	-	-	-
3	Average weight		672.1	mg	-	-
4	Uniformity of weight		-1.1 to + 1.5	%	-	± 5.0
5	Dissolution		96.4 to 102.5	%	500 mg	Q. Not less than 75
6	Related Substances					
	Azithromycin impurity B	IP-2022	Not detected	%	500 mg	Not more than 2.0
	Total other secondary Impurities		Not detected	%		Not more than 3.0
7	Assay: Each film coated tablet contains					
	Azithromycin as Dihydrate Eq. to Azithromycin (Anhydrous)	IP-2022	507.7 mg (i.e. 101.5 %)	mg	500 mg	450.0 mg to 550.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050132-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01937
Sample name: Azithral-500 (Azithromycin Tablets IP 500 mg)
Sample appearance: Light yellow coloured elongated biconvex film coated tablet, scored on one side and plain on other side
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 13 | Medicine: Azithromycin | Source: BRAND | Batch No: 2508000347 | Exp : Feb.27

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 22/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP-2022	Complies	-	-	-
3	Average weight		805.2	mg	-	-
4	Uniformity of weight		-1.5 to + 1.1	%	-	± 5.0
5	Dissolution		97.3 to 102.4	%	500 mg	Q. Not less than 75
6	Related Substances					
	Azithromycin impurity B	IP-2022	Not detected	%	500 mg	Not more than 2.0
	Total other secondary Impurities		Not detected	%		Not more than 3.0
7	Assay: Each film coated tablet contains					
	Azithromycin (as Dihydrate) equivalent to Azithromycin Anhydrous	IP-2022	509.3 mg (i.e. 101.9 %)	mg	500 mg	450.0 mg to 550.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050185-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02042
Sample name: Amoxycillin Capsule IP 500 mg
Sample appearance: Red/Red coloured unsealed hard gelatin capsule containing off white granular powder
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 14 | Medicine: Amoxicillin | Source: JAUSH | Batch No: GC4205 | Exp : Dec.26

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 19/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		691.6	mg	-	-
4	Average fill weight		597.6	mg	-	-
5	Uniformity of fill weight		-2.5 to +3.2	%	-	± 7.5
6	Dissolution		92.2 to 98.3	%	500 mg	Q. Not less than 80
7	Assay: Each hard gelatin capsule contains					
	Amoxycillin trihydrate Eq. to Amoxycillin	IP-2022	492.6 mg (i.e. 98.5 %)	mg	500 mg	450.0 mg to 550.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050186-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02043

Sample name: MOXILIUM- 500 (Amoxycillin Trihydrate Capsule IP)

Sample appearance: Yellow/Yellow coloured unsealed hard gelatin capsule containing light yellow granular powder and having imprinted “MOXILIUM 500” on both cap and body

Sample quantity: 45 Nos

Condition on receipt: Good

Sample packing: Sealed Pack

Environmental condition: Not Applicable

Customer provided details: S.R No : 15 | Medicine: Amoxicillin | Source: GENERIC | Batch No: SPAK24007 | Exp : Aug.26

Sample receipt date: 12/12/2025

Analysed between: 12/12/2025 to 19/12/2025

Sampling details: Not Sampled by Eureka

Sample seal no.: Not Applicable

Sampling procedure: Not Applicable

Sampling date: Not Applicable

Sampling location: Not Applicable

Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		707.5	mg	-	-
4	Average fill weight		607.2	mg	-	-
5	Uniformity of fill weight		-2.3 to +2.6	%	-	± 7.5
6	Dissolution		93.5 to 99.6	%	500 mg	Q. Not less than 80
7	Assay: Each hard gelatin capsule contains					
	Amoxycillin trihydrate Eq. to Amoxycillin	IP-2022	493.6 mg (i.e. 98.7 %)	mg	500 mg	450.0 mg to 550.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050187-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02044
Sample name: Amoxycillin Trihydrate Capsule IP 500 mg
Sample appearance: Yellow/Yellow coloured unsealed hard gelatin capsule containing off white granular powder and having imprinted “AMOXY” on cap and “500” on body
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 16 | Medicine: Amoxicillin | Source: DAVA | Batch No: BC-241017/D | Exp : Sep.26

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 19/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		687.6	mg	-	-
4	Average fill weight		592.2	mg	-	-
5	Uniformity of fill weight		-3.5 to +2.9	%	-	± 7.5
6	Dissolution		87.6 to 93.4	%	500 mg	Q. Not less than 80
7	Assay: Each hard gelatin capsule contains					
	Amoxycillin trihydrate Eq. to Amoxycillin	IP-2022	487.3 mg (i.e. 97.5 %)	mg	500 mg	450.0 mg to 550.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050188-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02045

Sample name: Cipmox 500 (Amoxycillin Trihydrate Capsule IP 500 mg)

Sample appearance: Yellow/Yellow coloured unsealed hard gelatin capsule containing off white granular powder and having imprinted “CIPMOX 500” on both cap and body

Sample quantity: 45 Nos

Condition on receipt: Good

Sample packing: Sealed Pack

Environmental condition: Not Applicable

Customer provided details: S.R No : 17 | Medicine: Amoxicillin | Source: BGENERIC | Batch No: 5KMO127 | Exp : Mar.27

Sample receipt date: 12/12/2025

Analysed between: 12/12/2025 to 19/12/2025

Sampling details: Not Sampled by Eureka

Sample seal no.: Not Applicable

Sampling procedure: Not Applicable

Sampling date: Not Applicable

Sampling location: Not Applicable

Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		695.8	mg	-	-
4	Average fill weight		593.4	mg	-	-
5	Uniformity of fill weight		-1.5 to +1.9	%	-	± 7.5
6	Dissolution		94.8 to 101.2	%	500 mg	Q. Not less than 80
7	Assay: Each hard gelatin capsule contains					
	Amoxycillin trihydrate Eq. to Amoxycillin	IP-2022	502.3 mg (i.e. 100.5%)	mg	500 mg	450.0 mg to 550.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050189-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02046
Sample name: MOKCAN- 500 (Amoxycillin Capsule IP 500 mg)
Sample appearance: Yellow coloured unsealed hard gelatin capsule containing off white granular powder
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 18 | Medicine: Amoxicillin | Source: BGENERIC | Batch No: AD25001 | Exp : Jan.27

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 19/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		680.4	mg	-	-
4	Average fill weight		583.5	mg	-	-
5	Uniformity of fill weight		-1.2 to +1.7	%	-	± 7.5
6	Dissolution		93.6 to 98.9	%	500 mg	Q. Not less than 80
7	Assay: Each hard gelatin capsule contains					
	Amoxycillin trihydrate Eq. to Amoxycillin	IP-2022	494.1 mg (i.e. 98.8 %)	mg	500 mg	450.0 mg to 550.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050190-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02047

Sample name: MOX CAPSULES 500 mg (Amoxycillin Trihydrate Capsule IP)

Sample appearance: Yellow/Yellow coloured unsealed hard gelatin capsule containing off white granular powder and having imprinted “MOX 500” on both cap and body

Sample quantity: 45 Nos

Condition on receipt: Good

Sample packing: Sealed Pack

Environmental condition: Not Applicable

Customer provided details: S.R No : 19 | Medicine: Amoxicillin | Source: BRAND | Batch No: DFG3177A | Exp : Apr.27

Sample receipt date: 12/12/2025

Analysed between: 12/12/2025 to 19/12/2025

Sampling details: Not Sampled by Eureka

Sample seal no.: Not Applicable

Sampling procedure: Not Applicable

Sampling date: Not Applicable

Sampling location: Not Applicable

Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		720.2	mg	-	-
4	Average fill weight		615.9	mg	-	-
5	Uniformity of fill weight		-1.8 to +1.3	%	-	± 7.5
6	Dissolution		96.2 to 104.1	%	500 mg	Q. Not less than 80
7	Assay: Each hard gelatin capsule contains					
	Amoxycillin trihydrate Eq. to Amoxycillin	IP-2022	505.5 mg (i.e. 101.1 %)	mg	500 mg	450.0 mg to 550.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050191-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02048

Sample name: Novamox 500 (Amoxycillin Trihydrate Capsule IP 500 mg)

Sample appearance: Dark orange/dark orange coloured unsealed hard gelatin capsule containing off white granular powder and having imprinted “Novamox 500” on both cap and body

Sample quantity: 45 Nos

Condition on receipt: Good

Sample packing: Sealed Pack

Environmental condition: Not Applicable

Customer provided details: S.R No : 20 | Medicine: Amoxicillin | Source: BRAND | Batch No: 5KMO189 | Exp : Apr.27

Sample receipt date: 12/12/2025

Analysed between: 12/12/2025 to 19/12/2025

Sampling details: Not Sampled by Eureka

Sample seal no.: Not Applicable

Sampling procedure: Not Applicable

Sampling date: Not Applicable

Sampling location: Not Applicable

Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		697.4	mg	-	-
4	Average fill weight		592.6	mg	-	-
5	Uniformity of fill weight		-1.4 to +1.1	%	-	± 7.5
6	Dissolution		97.2 to 103.3	%	500 mg	Q. Not less than 80
7	Assay: Each hard gelatin capsule contains					
	Amoxycillin trihydrate Eq. to Amoxycillin	IP-2022	503.9 mg (i.e. 100.8%)	mg	500 mg	450.0 mg to 550.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050302-01
Report date: 28/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01938
Sample name: Ranitidine Hydrochloride Tablets IP 150 mg
Sample appearance: Orange coloured round shaped biconvex film coated tablet, plain on both sides
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No: 21 | Medicine: Ranitidine | Source: JAUSH | Batch No: RDHT-1053 | Exp: Jan.28

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 23/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		291.7	mg	-	-
4	Uniformity of weight		-2.5 to + 1.8	%	-	± 5.0
5	Dissolution		88.5 to 95.3	%	150 mg	Q. Not less than 80
6	Related substances					
	Any secondary impurity	IP-2022	Not detected	%	150 mg	Not more than 0.5
	One secondary impurity		Not detected	%		Not more than 0.3
	Three other secondary Impurities		Not detected	%		Not more than 0.1
7	Assay: Each film coated tablet contains					
	Ranitidine Hydrochloride Equivalent to Ranitidine	IP- 2022	145.8 mg (i.e. 97.2 %)	mg	150 mg	135.0 mg to 165.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050303-01
Report date: 28/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01939
Sample name: SWASTAC-150 (Ranitidine Tablets IP 150 mg)
Sample appearance: Orange coloured round shaped biconvex film coated tablet, plain on both sides
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 22 | Medicine: Ranitidine | Source: GENADH | Batch No: 169DG02 | Exp : Sep.26

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 23/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		333.1	mg	-	-
4	Uniformity of weight		-1.1 to + 1.4	%	-	± 5.0
5	Dissolution		90.7 to 96.4	%	150 mg	Q. Not less than 80
6	Related substances					
	Any secondary impurity	IP-2022	Not detected	%	150 mg	Not more than 0.5
	One secondary impurity		Not detected	%		Not more than 0.3
	Three other secondary Impurities		Not detected	%		Not more than 0.1
7	Assay: Each film coated tablet contains					
	Ranitidine Hydrochloride Eq. to Ranitidine	IP- 2022	144.5 mg (i.e. 96.3 %)	mg	150 mg	135.0 mg to 165.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050304-01
Report date: 28/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01940
Sample name: HISTAC-150 (Ranitidine Hydrochloride Tablets IP)
Sample appearance: White round shaped biconvex film coated tablet, having inscribed “HISTAC” on one side and “150” on other side
Sample quantity: 60 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 23 | Medicine: Ranitidine | Source: BGENERIC | Batch No: DFF7844A | Exp : May.26

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 23/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		305.5	mg	-	-
4	Uniformity of weight		-1.7 to + 1.2	%	-	± 5.0
5	Dissolution		95.6 to 102.3	%	150 mg	Q. Not less than 80
6	Related substances					
	Any secondary impurity	IP-2022	Not detected	%	150 mg	Not more than 0.5
	One secondary impurity		Not detected	%		Not more than 0.3
	Three other secondary Impurities		Not detected	%		Not more than 0.1
7	Assay: Each film coated tablet contains					
	Ranitidine Hydrochloride Equivalent to Ranitidine	IP- 2022	151.7 mg (i.e. 101.1 %)	mg	150 mg	135.0 mg to 165.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050305-01
Report date: 28/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01941

Sample name: RANITIN-150 (Ranitidine Hydrochloride Tablets IP)

Sample appearance: White round shaped biconvex film coated tablet, having inscribed “RANITIN 150” on one side and plain on other side

Sample quantity: 40 Nos

Condition on receipt: Good

Sample packing: Sealed Pack

Environmental condition: Not Applicable

Customer provided details: S.R No : 24 | Medicine: Ranitidine | Source: BRAND | Batch No: 2CH3M004 | Exp : Mar.27

Sample receipt date: 12/12/2025

Analysed between: 12/12/2025 to 23/12/2025

Sampling details: Not Sampled by Eureka

Sample seal no.: Not Applicable

Sampling procedure: Not Applicable

Sampling date: Not Applicable

Sampling location: Not Applicable

Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		270.5	mg	-	-
4	Uniformity of weight		-1.7 to + 1.1	%	-	± 5.0
5	Dissolution		95.3 to 102.9	%	150 mg	Q. Not less than 80
6	Related substances					
	Any secondary impurity	IP-2022	Not detected	%	150 mg	Not more than 0.5
	One secondary impurity		Not detected	%		Not more than 0.3
	Three other secondary Impurities		Not detected	%		Not more than 0.1
7	Assay: Each film coated tablet contains					
	Ranitidine Hydrochloride	IP- 2022	152.4 mg	mg	150 mg	135.0 mg to 165.0 mg

	Equivalent to Ranitidine		(i.e. 101.6 %)			(i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050306-01
Report date: 28/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01942
Sample name: RANTAC 150 (Ranitidine Tablets IP 150 mg)
Sample appearance: Orange coloured round shaped biconvex film coated tablet, plain on both sides
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 25 | Medicine: Ranitidine | Source: BRAND | Batch No: TR325135 | Exp : Nov.26

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 23/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		193.1	mg	-	-
4	Uniformity of weight		-2.4 to + 2.0	%	-	± 5.0
5	Dissolution		94.9 to 100.2	%	150 mg	Q. Not less than 80
6	Related substances					
	Any secondary impurity	IP-2022	Not detected	%	150 mg	Not more than 0.5
	One secondary impurity		Not detected	%		Not more than 0.3
	Three other secondary Impurities		Not detected	%		Not more than 0.1
7	Assay: Each film coated tablet contains					
	Ranitidine Hydrochloride Equivalent to Ranitidine	IP- 2022	151.4 mg (i.e.100.9 %)	mg	150 mg	135.0 mg to 165.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050307-01
Report date: 28/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01943
Sample name: Pantoprazole Gastro-Resistant Tablets IP 40 mg
Sample appearance: Green coloured round biconvex enteric coated tablet, plain on both sides
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 22/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

Customer provided details: S.R No : 26 | Medicine: Pantoprazole | Source: JAUSH | Batch No: THE25013AL | Exp : Jun.27

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP- 2022	Complies	-	-	-
3	Average weight		120.7	mg	-	-
4	Uniformity of weight		-1.9 to + 2.7	%	-	± 7.5
5	Related substances					
	Pantoprazole related compound A	IP 2022	Not detected	%	40 mg	Not more than 0.5
	Pantoprazole related compound D		Not detected			
	Pantoprazole related compound F		Not detected			
	Pantoprazole related compound B		Not detected			Not more than 0.3
	Any other secondary impurity		Not detected			Not more than 0.2
	Sum of all the secondary impurities		Not detected			Not more than 1.0
6	Dissolution					
	A. Acid stage	IP- 2022	1.2 to 4.6	%	40 mg	Not more than 10
	B. Buffer stage		83.8 to 87.9	%		Q. Not less than 75

7	Assay: Each enteric coated tablet contains					
	Pantoprazole sodium Eq. to Pantoprazole	IP- 2022	38.9 mg (i.e. 97.3 %)	mg	40 mg	36.0 mg to 44.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

Citizens Generic Vs Branded Drugs Project

**Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024**

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01944

Sample name: Pantoprazole Gastro-Resistant Tablets IP 40 mg

Sample appearance: Yellow coloured round biconvex enteric coated tablet, plain on both sides

Sample quantity: 45 Nos

Condition on receipt: Good

Sample packing: Sealed Pack

Environmental condition: Not Applicable

Customer provided details: S.R No : 27 | Medicine: Pantoprazole | Source: GENADH | Batch No: PGW25003 | Exp : Apr.27

Sample receipt date: 12/12/2025

Analysed between: 12/12/2025 to 22/12/2025

Sampling details: Not Sampled by Eureka

Sample seal no.: Not Applicable

Sampling procedure: Not Applicable

Sampling date: Not Applicable

Sampling location: Not Applicable

Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP- 2022	Complies	-	-	-
3	Average weight		126.2	mg	-	-
4	Uniformity of weight		-2.0 to + 3.5	%	-	± 7.5
5	Related substances					
	Pantoprazole related compound A	IP 2022	Not detected	%	40 mg	Not more than 0.5
	Pantoprazole related compound D		Not detected			
	Pantoprazole related compound F		Not detected			
	Pantoprazole related compound B		Not detected			Not more than 0.3
	Any other secondary impurity		Not detected			Not more than 0.2
	Sum of all the secondary impurities		Not detected			Not more than 1.0
6	Dissolution					
	A. Acid stage	IP- 2022	1.9 to 5.5	%	40 mg	Not more than 10
	B. Buffer stage		86.9 to 93.4	%		Q. Not less than 75

7	Assay: Each enteric coated tablet contains					
	Pantoprazole sodium Eq. to Pantoprazole	IP- 2022	39.1 mg (i.e. 97.8 %)	mg	40 mg	36.0 mg to 44.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050309-01
Report date: 28/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01945

Sample name: Pantoziv 40 (Pantoprazole Gastro-Resistant Tablets IP)

Sample appearance: Yellow coloured round biconvex enteric coated tablet, plain on both sides

Sample quantity: 40 Nos

Condition on receipt: Good

Sample packing: Sealed Pack

Environmental condition: Not Applicable

Customer provided details: S.R No : 28 | Medicine: Pantoprazole | Source: GENERIC | Batch No: GD25131 | Exp : Jul.27

Sample receipt date: 12/12/2025

Analysed between: 12/12/2025 to 22/12/2025

Sampling details: Not Sampled by Eureka

Sample seal no.: Not Applicable

Sampling procedure: Not Applicable

Sampling date: Not Applicable

Sampling location: Not Applicable

Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP- 2022	Complies	-	-	-
3	Average weight		205.9	mg	-	-
4	Uniformity of weight		-1.7 to + 2.2	%	-	± 7.5
5	Related substances					
	Pantoprazole related compound A	IP 2022	Not detected	%	40 mg	Not more than 0.5
	Pantoprazole related compound D		Not detected			
	Pantoprazole related compound F		Not detected			
	Pantoprazole related compound B		Not detected			Not more than 0.3
	Any other secondary impurity		Not detected			Not more than 0.2
	Sum of all the secondary impurities		Not detected			Not more than 1.0
6	Dissolution					
	A. Acid stage	IP- 2022	1.5 to 5.1	%	40 mg	Not more than 10

	B. Buffer stage		84.9 to 92.7	%		Q. Not less than 75
7	Assay: Each enteric coated tablet contains					
	Pantoprazole sodium Eq. to Pantoprazole	IP- 2022	38.7 mg (i.e. 96.8 %)	mg	40 mg	36.0 mg to 44.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050310-01
Report date: 28/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01946
Sample name: Pantosec (Pantoprazole Tablets IP 40 mg)
Sample appearance: Yellow coloured round biconvex enteric coated tablet, plain on both sides
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 22/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

Customer provided details: S.R No : 29 | Medicine: Pantoprazole | Source: BGENERIC | Batch No: PNS250614 | Exp : May.27

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP- 2022	Complies	-	-	-
3	Average weight		84.6	mg	-	-
4	Uniformity of weight		-2.3 to + 3.3	%	-	± 7.5
5	Related substances					
	Pantoprazole related compound A	IP 2022	Not detected	%	40 mg	Not more than 0.5
	Pantoprazole related compound D		Not detected			
	Pantoprazole related compound F		Not detected			
	Pantoprazole related compound B		Not detected			Not more than 0.3
	Any other secondary impurity		Not detected			Not more than 0.2
	Sum of all the secondary impurities		Not detected			Not more than 1.0
6	Dissolution					
	A. Acid stage	IP- 2022	1.4 to 3.2	%	40 mg	Not more than 10

	B. Buffer stage		91.1 to 99.5	%		Q. Not less than 75
7	Assay: Each enteric coated tablet contains					
	Pantoprazole sodium Eq. to Pantoprazole	IP- 2022	40.6 mg (i.e. 101.5 %)	mg	40 mg	36.0 mg to 44.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050311-01
Report date: 28/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01947
Sample name: PENTALOC 40 (Pantoprazole Gastro-Resistant Tablets IP 40 mg)
Sample appearance: Yellow coloured oval shaped biconvex enteric coated tablet, plain on both sides
Sample quantity: 45 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 30 | Medicine: Pantoprazole | Source: BGENERIC | Batch No: JKFD25014 | Exp : Aug.28

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 22/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP- 2022	Complies	-	-	-
3	Average weight		210.8	mg	-	-
4	Uniformity of weight		-0.9 to + 2.1	%	-	± 7.5
5	Related substances					
	Pantoprazole related compound A	IP 2022	Not detected	%	40 mg	Not more than 0.5
	Pantoprazole related compound D		Not detected			
	Pantoprazole related compound F		Not detected			
	Pantoprazole related compound B		Not detected			Not more than 0.3
	Any other secondary impurity		Not detected			Not more than 0.2
	Sum of all the secondary impurities		Not detected			Not more than 1.0
6	Dissolution					
	A. Acid stage	IP- 2022	1.5 to 3.9	%	40 mg	Not more than 10

	B. Buffer stage		92.6 to 100.4	%		Q. Not less than 75
7	Assay: Each gastro-resistant tablet contains					
	Pantoprazole sodium Eq. to Pantoprazole	IP- 2022	40.6 mg (i.e. 101.5 %)	mg	40 mg	36.0 mg to 44.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050312-01
Report date: 28/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01948

Sample name: Pantodac 40 (Pantoprazole Gastro-Resistant Tablets IP)

Sample appearance: Yellow coloured oval shaped biconvex gastro-resistant coated tablet, plain on both sides

Sample quantity: 45 Nos

Condition on receipt: Good

Sample packing: Sealed Pack

Environmental condition: Not Applicable

Customer provided details: S.R No : 31 | Medicine: Pantoprazole | Source: BRAND | Batch No: I501615 | Exp : Mar.28

Sample receipt date: 12/12/2025

Analysed between: 12/12/2025 to 22/12/2025

Sampling details: Not Sampled by Eureka

Sample seal no.: Not Applicable

Sampling procedure: Not Applicable

Sampling date: Not Applicable

Sampling location: Not Applicable

Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP- 2022	Complies	-	-	-
3	Average weight		205.8	mg	-	-
4	Uniformity of weight		-1.4 to + 2.3	%	-	± 7.5
5	Related substances					
	Pantoprazole related compound A	IP 2022	Not detected	%	40 mg	Not more than 0.5
	Pantoprazole related compound D		Not detected			
	Pantoprazole related compound F		Not detected			
	Pantoprazole related compound B		Not detected			Not more than 0.3
	Any other secondary impurity		Not detected			Not more than 0.2
	Sum of all the secondary impurities		Not detected			Not more than 1.0
6	Dissolution					
	A. Acid stage	IP- 2022	1.1 to 4.3	%	40 mg	Not more than 10

	B. Buffer stage		93.8 to 102.5	%		Q. Not less than 75
7	Assay: Each gastro-resistant tablet contains					
	Pantoprazole sodium Eq. to Pantoprazole	IP- 2022	40.3 mg (i.e. 100.8 %)	mg	40 mg	36.0 mg to 44.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050313-01
Report date: 28/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01949
Sample name: Pantocid 40 (Pantoprazole Tablets IP)
Sample appearance: Yellow coloured round biconvex enteric coated tablet, plain on both sides
Sample quantity: 45 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 32 | Medicine: Pantoprazole | Source: BRAND | Batch No: GTG2276A | Exp : Jun.28

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 22/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP- 2022	Complies	-	-	-
3	Average weight		217.4	mg	-	-
4	Uniformity of weight		-2.1 to + 2 .6	%	-	± 7.5
5	Related substances					
	Pantoprazole related compound A	IP 2022	Not detected	%	40 mg	Not more than 0.5
	Pantoprazole related compound D		Not detected			
	Pantoprazole related compound F		Not detected			
	Pantoprazole related compound B		Not detected			Not more than 0.3
	Any other secondary impurity		Not detected			Not more than 0.2
	Sum of all the secondary impurities		Not detected			Not more than 1.0
6	Dissolution					
	A. Acid stage	IP- 2022	1.2 to 4.6	%	40 mg	Not more than 10

	B. Buffer stage		94.6 to 101.4	%		Q. Not less than 75
7	Assay: Each enteric coated tablet contains					
	Pantoprazole sodium Eq. to Pantoprazole	IP- 2022	41.1 mg (i.e. 102.8 %)	mg	40 mg	36.0 mg to 44.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050133-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01950
Sample name: Omeprazole Gasto-resistant Capsule IP 20 mg
Sample appearance: Blue/white coloured unsealed hard gelatin capsule containing white round pellets
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 33 | Medicine: Omeprazole | Source: JAUSH | Batch No: Z25-812 | Exp : Jun.27

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 22/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		253.2	mg	-	-
4	Average fill weight		202.6	mg	-	-
5	Uniformity of fill weight		-1.8 to +2.6	%	-	± 7.5
6	Dissolution					
	A. Acid stage	IP-2022	1.1 to 2.3	%	20 mg	Not more than 10
	B. Buffer stage		82.2 to 88.3	%		Q. Not less than 70
7	Loss on drying		1.21	%	-	Not more than 3
8	Assay: Each hard gelatin capsule contains					
	Omeprazole	IP-2022	19.1 mg (i.e. 95.5 %)	mg	20 mg	18.0 mg to 22.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050134-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01951
Sample name: Swomez-C20 capsules (Omeprazole Capsules IP 20 mg)
Sample appearance: Pink/white clear transparent unsealed hard gelatin capsule containing white round pellets
Sample quantity: 50 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 34 | Medicine: Omeprazole | Source: GENADH | Batch No: SD0466 | Exp : Aug.27

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 22/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		335.4	mg	-	-
4	Average fill weight		274.8	mg	-	-
5	Uniformity of fill weight		-2.2 to +3.2	%	-	± 7.5
6	Dissolution					
	A. Acid stage	IP-2022	3.5 to 5.9	%	20 mg	Not more than 10
	B. Buffer stage		81.4 to 86.4	%		Q. Not less than 70
7	Loss on drying		1.81	%	-	Not more than 3
8	Assay: Each hard gelatin capsule contains					
	Omeprazole	IP-2022	18.9 mg (i.e. 94.5 %)	mg	20 mg	18.0 mg to 22.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050135-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01952
Sample name: Omzed 20 (Omeprazole Capsules IP 20 mg)
Sample appearance: Pink/white clear transparent unsealed hard gelatin capsule containing off white round pellets
Sample quantity: 45 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 22/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

Customer provided details: S.R No : 35 | Medicine: Omeprazole | Source: GENERIC | Batch No: TBL-24C1116 | Exp : Dec.26

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		255.5	mg	-	-
4	Average fill weight		210.8	mg	-	-
5	Uniformity of fill weight		-2.6 to +1.7	%	-	± 7.5
6	Dissolution					
	A. Acid stage	IP-2022	3.4 to 6.8	%	20 mg	Not more than 10
	B. Buffer stage		84.6 to 89.7	%		Q. Not less than 70
7	Loss on drying		1.26	%	-	Not more than 3
8	Assay: Each hard gelatin capsule contains					
	Omeprazole	IP-2022	19.3 mg (i.e. 96.5 %)	mg	20 mg	18.0 mg to 22.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050136-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01953

Sample name: Omee (Omeprazole Gasto-resistant Capsule IP 20 mg)

Sample appearance: Pink/white clear transparent unsealed hard gelatin capsule containing white round pellets and having imprinted "ALKEM" on cap and "OMEE" on body

Sample quantity: 40 Nos

Condition on receipt: Good

Sample packing: Sealed Pack

Environmental condition: Not Applicable

Customer provided details: S.R No : 36 | Medicine: Omeprazole | Source: BGENERIC | Batch No: 25281541 | Exp : Jun.27

Sample receipt date: 12/12/2025

Analysed between: 12/12/2025 to 22/12/2025

Sampling details: Not Sampled by Eureka

Sample seal no.: Not Applicable

Sampling procedure: Not Applicable

Sampling date: Not Applicable

Sampling location: Not Applicable

Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		326.4	mg	-	-
4	Average fill weight		264.9	mg	-	-
5	Uniformity of fill weight		-1.2 to +1.9	%	-	± 7.5
6	Dissolution					
	A. Acid stage	IP-2022	1.5 to 3.3	%	20 mg	Not more than 10
	B. Buffer stage		92.2 to 97.6	%		Q. Not less than 70
7	Loss on drying		1.05	%	-	Not more than 3
8	Assay: Each hard gelatin capsule contains					
	Omeprazole	IP-2022	20.3 mg (i.e. 101.5 %)	mg	20 mg	18.0 mg to 22.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050137-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH), Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01954

Sample name: Omecip (Omeprazole Gasto-resistant Capsules IP 20 mg)

Sample appearance: Pink/white clear transparent unsealed hard gelatin capsule containing white round pellets

Sample quantity: 45 Nos

Condition on receipt: Good

Sample packing: Sealed Pack

Environmental condition: Not Applicable

Customer provided details: S.R No : 37 | Medicine: Omeprazole | Source: BGENERIC | Batch No: MEP25009 | Exp : Mar.27

Sample receipt date: 12/12/2025

Analysed between: 12/12/2025 to 22/12/2025

Sampling details: Not Sampled by Eureka

Sample seal no.: Not Applicable

Sampling procedure: Not Applicable

Sampling date: Not Applicable

Sampling location: Not Applicable

Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		230.7	mg	-	-
4	Average fill weight		182.5	mg	-	-
5	Uniformity of fill weight		-2.1 to +1.5	%	-	± 7.5
6	Dissolution					
	A. Acid stage	IP-2022	2.1 to 3.6	%	20 mg	Not more than 10
	B. Buffer stage		95.2 to 101.5	%		Q. Not less than 70
7	Loss on drying		1.08	%	-	Not more than 3
8	Assay: Each hard gelatin capsule contains					
	Omeprazole	IP-2022	20.5 mg (i.e. 102.5 %)	mg	20 mg	18.0 mg to 22.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050138-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01955

Sample name: Ocid 20 (Omeprazole Gasto-resistant Capsules IP 20 mg)

Sample appearance: Light Brown/slightly pink coloured unsealed hard gelatin capsule containing white round pellets and having imprinted “Zydus Cadila” on cap and “Ocid20” on body

Sample quantity: 40 Nos

Condition on receipt: Good

Sample packing: Sealed Pack

Environmental condition: Not Applicable

Customer provided details: S.R No : 38 | Medicine: Omeprazole | Source: BRAND | Batch No: I501479 | Exp : Dec.26

Sample receipt date: 12/12/2025

Analysed between: 12/12/2025 to 22/12/2025

Sampling details: Not Sampled by Eureka

Sample seal no.: Not Applicable

Sampling procedure: Not Applicable

Sampling date: Not Applicable

Sampling location: Not Applicable

Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		140.9	mg	-	-
4	Average fill weight		102.7	mg	-	-
5	Uniformity of fill weight		-0.9 to +2.3	%	-	± 7.5
6	Dissolution					
	A. Acid stage	IP-2022	1.9 to 3.5	%	20 mg	Not more than 10
	B. Buffer stage		94.8 to 104.2	%		Q. Not less than 70
7	Loss on drying		1.23	%	-	Not more than 3
8	Assay: Each hard gelatin capsule contains					
	Omeprazole	IP-2022	20.6 mg (i.e. 103.0 %)	mg	20 mg	18.0 mg to 22.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050139-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01956
Sample name: OMEZ 20 (Omeprazole Capsules IP 20 mg)
Sample appearance: Pink/white clear transparent unsealed hard gelatin capsule containing white round pellets and having imprinted a logo on cap and "OMEZ" on body
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 39 | Medicine: Omeprazole | Source: BRAND | Batch No: E2500805 | Exp : Mar.28

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 22/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		226.7	mg	-	-
4	Average fill weight		179.5	mg	-	-
5	Uniformity of fill weight		-1.5 to +2.1	%	-	± 7.5
6	Dissolution					
	A. Acid stage	IP-2022	1.5 to2.6	%	20 mg	Not more than 10
	B. Buffer stage		93.7 to 101.6	%		Q. Not less than 70
7	Loss on drying		1.41	%	-	Not more than 3
8	Assay: Each hard gelatin capsule contains					
	Omeprazole	IP-2022	20.2 mg (i.e. 101.0 %)	mg	20 mg	18.0 mg to 22.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050314-01
Report date: 28/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01957
Sample name: Metformin hydrochloride Tablets IP 500 mg
Sample appearance: White elongated biconvex uncoated tablet, plain on both sides
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 40 | Medicine: Metformin | Source: JAUSH | Batch No: CT 25260313 | Exp : Apr.27

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 24/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A, B & C)	IP-2022	Complies	-	-	-
3	Average weight		650.1	mg	-	-
4	Uniformity of weight		-1.1 to + 1.6	%	-	± 5.0
5	Dissolution		complies	%	500 mg	Q. Not less than 70
6	Related substances					
	Dicyandiamide	IP-2022	Not detected	%	500 mg	Not more than 0.02
	Any other secondary impurity		Not detected	%		Not more than 0.1
7	Assay: Each uncoated tablet contains					
	Metformin hydrochloride	IP- 2022	492.8 mg (i.e. 98.6 %)	mg	500 mg	475.0 mg to 525.0 mg (i.e. 95.0 % to 105.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050316-01
Report date: 28/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01959
Sample name: Metformin hydrochloride Tablets IP 500 mg
Sample appearance: White elongated biconvex uncoated tablet, scored on one side and plain on other side
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 42 | Medicine: Metformin | Source: DAVA | Batch No: AD25087 | Exp : Jun.27

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 24/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A, B & C)	IP-2022	Complies	-	-	-
3	Average weight		765.1	mg	-	-
4	Uniformity of weight		-1.3 to + 1.1	%	-	± 5.0
5	Dissolution		94.6 to 99.1	%	500 mg	Q. Not less than 70
6	Related substances					
	Dicyandiamide	IP-2022	Not detected	%	500 mg	Not more than 0.02
	Any other secondary impurity		Not detected	%		Not more than 0.1
7	Assay: Each uncoated tablet contains					
	Metformin hydrochloride	IP- 2022	491.6 mg (i.e. 98.3 %)	mg	500 mg	475.0 mg to 525.0 mg (i.e. 95.0 % to 105.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050318-01
Report date: 28/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01961

Sample name: Glycomet (Metformin hydrochloride Tablets IP 500 mg)

Sample appearance: White round flat uncoated tablet, having inscribed “USV” on one side and plain on other side

Sample quantity: 40 Nos

Condition on receipt: Good

Sample packing: Sealed Pack

Environmental condition: Not Applicable

Customer provided details: S.R No : 44 | Medicine: Metformin | Source: BGENERIC | Batch No: 56001928 | Exp : May.28

Sample receipt date: 12/12/2025

Analysed between: 12/12/2025 to 24/12/2025

Sampling details: Not Sampled by Eureka

Sample seal no.: Not Applicable

Sampling procedure: Not Applicable

Sampling date: Not Applicable

Sampling location: Not Applicable

Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A, B & C)	IP-2022	Complies	-	-	-
3	Average weight		602.5	mg	-	-
4	Uniformity of weight		-0.8 to + 1.2	%	-	± 5.0
5	Dissolution		97.9 to 102.5	%	500 mg	Q. Not less than 70
6	Related substances					
	Dicyandiamide	IP-2022	Not detected	%	500 mg	Not more than 0.02
	Any other secondary impurity		Not detected	%		Not more than 0.1
7	Assay: Each uncoated tablet contains					
	Metformin hydrochloride	IP- 2022	505.7 mg (i.e. 101.1 %)	mg	500 mg	475.0 mg to 525.0 mg (i.e. 95.0 % to 105.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050319-01
Report date: 28/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01962
Sample name: GLYCIPHAGE (Metformin Tablets IP 500 mg)
Sample appearance: White elongated biconcave uncoated tablet, having inscribed "GLYCIPHAGE" on one side and scored on other side
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 45 | Medicine: Metformin | Source: BRAND | Batch No: G0375084 | Exp : Mar.28

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 24/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A, B & C)	IP-2022	Complies	-	-	-
3	Average weight		557.7	mg	-	-
4	Uniformity of weight		-1.3 to + 0.8	%	-	± 5.0
5	Dissolution		96.5 to 103.6	%	500 mg	Q. Not less than 70
6	Related substances					
	Dicyandiamide	IP-2022	Not detected	%	500 mg	Not more than 0.02
	Any other secondary impurity		Not detected	%		Not more than 0.1
7	Assay: Each uncoated tablet contains					
	Metformin hydrochloride	IP- 2022	502.8 mg (i.e. 100.6 %)	mg	500 mg	475.0 mg to 525.0 mg (i.e. 95.0 % to 105.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050192-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02049
Sample name: Atorvastatin Tablets IP 10 mg
Sample appearance: White diamond shaped biconvex film coated tablet, plain on both sides
Sample quantity: 30 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 46 | Medicine: Atorvastatin | Source: JAUSH | Batch No: BRF06037B | Exp : May.28

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 22/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP-2022	Complies	-	-	-
3	Average weight		134.5	mg	-	-
4	Dissolution		82.5 to 87.7	%	10 mg	Q. Not less than 70
5	Uniformity of content		95.1 to 101.4	%		85.0 to 115.0
6	Related Substances					
	Any secondary Impurity	IP-2022	Not detected	%	10 mg	NMT 1.0
	Sum of all the secondary Impurities		Not detected	%		NMT 4.0
7	Assay: Each film coated tablet contains					
	Atorvastatin Calcium Equivalent to Atorvastatin	IP-2022	9.55 mg (i.e. 95.5 %)	mg	10 mg	9.0 mg to 11.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050193-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02050
Sample name: ATR-10 (Atorvastatin Tablets IP)
Sample appearance: White round shaped biconvex film coated tablet, plain on both sides
Sample quantity: 45 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 22/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

Customer provided details: S.R No : 47 | Medicine: Atorvastatin | Source: GENERIC | Batch No: KTT250291A | Exp : Feb.27

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP-2022	Complies	-	-	-
3	Average weight		168.9	mg	-	-
4	Dissolution		85.7 to 89.8	%	10 mg	Q. Not less than 70
5	Uniformity of content		94.6 to 102.5	%		85.0 to 115.0
6	Related Substances					
	Any secondary Impurity	IP-2022	Not detected	%	10 mg	NMT 1.0
	Sum of all the secondary Impurities		Not detected	%		NMT 4.0
7	Assay: Each film coated tablet contains					
	Atorvastatin Calcium Eq. to Atorvastatin	IP-2022	9.68 mg (i.e. 96.8 %)	mg	10 mg	9.0 mg to 11.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050194-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02051
Sample name: Atorvastatin Tablets IP 10 mg
Sample appearance: Brick red colored round shaped biconvex film coated tablet, plain on both sides
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 48 | Medicine: Atorvastatin | Source: DAVA | Batch No: CKX03ABA | Exp : May.27

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 22/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP-2022	Complies	-	-	-
3	Average weight		147.4	mg	-	-
4	Dissolution		85.8 to 92.4	%	10 mg	Q. Not less than 70
5	Uniformity of content		94.6 to 103.5	%		85.0 to 115.0
6	Related Substances					
	Any secondary Impurity	IP-2022	Not detected	%	10 mg	NMT 1.0
	Sum of all the secondary Impurities		Not detected	%		NMT 4.0
7	Assay: Each film coated tablet contains					
	Atorvastatin Calcium Eq. to Atorvastatin	IP-2022	9.72 mg (i.e. 97.2 %)	mg	10 mg	9.0 mg to 11.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050195-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02052
Sample name: ATORBEST 10 (Atorvastatin Tablets IP 10 mg)
Sample appearance: White round shaped biconvex film coated tablet, plain on both sides
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 49 | Medicine: Atorvastatin | Source: BGENERIC | Batch No: JKAL25015 | Exp : Jul.27

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 22/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP-2022	Complies	-	-	-
3	Average weight		154.2	mg	-	-
4	Dissolution		93.4 to 102.5	%	10 mg	Q. Not less than 70
5	Uniformity of content		96.8 to 102.5	%		85.0 to 115.0
6	Related Substances					
	Any secondary Impurity	IP-2022	Not detected	%	10 mg	NMT 1.0
	Sum of all the secondary Impurities		Not detected	%		NMT 4.0
7	Assay: Each film coated tablet contains					
	Atorvastatin Calcium Equivalent to Atorvastatin	IP-2022	10.23 mg (i.e. 102.3 %)	mg	10 mg	9.0 mg to 11.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050196-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02053
Sample name: Lipvas 10 (Atorvastatin Tablets IP 10 mg)
Sample appearance: White oval shaped biconvex film coated tablet, plain on both sides
Sample quantity: 60 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 50 | Medicine: Atorvastatin | Source: BGENERIC | Batch No: 5BA0141 | Exp : Dec.26

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 22/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP-2022	Complies	-	-	-
3	Average weight		153.3	mg	-	-
4	Dissolution		96.4 to 102.1	%	10 mg	Q. Not less than 70
5	Uniformity of content		97.2 to 102.5	%		85.0 to 115.0
6	Related Substances					
	Any secondary Impurity	IP-2022	Not detected	%	10 mg	NMT 1.0
	Sum of all the secondary Impurities		Not detected	%		NMT 4.0
7	Assay: Each film coated tablet contains					
	Atorvastatin Calcium Equivalent to Atorvastatin	IP-2022	10.27 mg (i.e. 102.7 %)	mg	10 mg	9.0 mg to 11.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050197-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02054
Sample name: Atcor 10 (Atorvastatin Tablets IP 10 mg)
Sample appearance: White diamond shaped biconvex film coated tablet, having inscribed “10” on one side and “A” on other side
Sample quantity: 45 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 51 | Medicine: Atorvastatin | Source: BRAND | Batch No: E2500729 | Exp : Mar.27

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 22/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP-2022	Complies	-	-	-
3	Average weight		130.2	mg	-	-
4	Dissolution		96.7 to 103.5	%	10 mg	Q. Not less than 70
5	Uniformity of content		96.8 to 102.8	%		85.0 to 115.0
6	Related Substances					
	Any secondary Impurity	IP-2022	Not detected	%	10 mg	NMT 1.0
	Sum of all the secondary Impurities		Not detected	%		NMT 4.0
7	Assay: Each film coated tablet contains					
	Atorvastatin Calcium Equivalent to Atorvastatin	IP-2022	10.31 mg (i.e.103.1 %)	mg	10 mg	9.0 mg to 11.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050198-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02055
Sample name: Atorlip-10 (Atorvastatin Tablets IP 10 mg)
Sample appearance: White oval shaped biconvex film coated tablet, plain on both sides
Sample quantity: 45 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 22/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

Customer provided details: S.R No : 52 | Medicine: Atorvastatin | Source: BRAND | Batch No: 5SN1676 | Exp : Jun.28

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP-2022	Complies	-	-	-
3	Average weight		154.5	mg	-	-
4	Dissolution		97.4 to 102.9	%	10 mg	Q. Not less than 70
5	Uniformity of content		96.6 to 103.5	%		85.0 to 115.0
6	Related Substances					
	Any secondary Impurity	IP-2022	Not detected	%	10 mg	NMT 1.0
	Sum of all the secondary Impurities		Not detected	%		NMT 4.0
7	Assay: Each film coated tablet contains					
	Atorvastatin Calcium Equivalent to Atorvastatin	IP-2022	10.24 mg (i.e. 102.4 %)	mg	10 mg	9.0 mg to 11.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050201-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01963
Sample name: Amlodipine Tablets IP 5 mg
Sample appearance: White round flat uncoated tablet, scored on one side and plain on other side
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 53 | Medicine: Amlodipine | Source: JAUSH | Batch No: 2506108 | Exp : May.27

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 18/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP-2022	Complies	-	-	-
3	Average weight		149.1	mg	-	-
4	Dissolution		88.2 to 95.1	%	5 mg	Q. Not less than 75
5	Uniformity of content		94.2 to 103.1	%		85.0 to 115.0
6	Related Substances					
	Amlodipine impurity D	IP-2022	Not detected	%	5 mg	Not more than 0.5
	Sum of all other secondary Impurities		Not detected	%		Not more than 0.5
7	Assay: Each uncoated tablet contains					
	Amlodipine Besylate Eq. to Amlodipine	IP-2022	4.79 mg (i.e. 95.8 %)	mg	5 mg	9.0 mg to 11.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050140-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01964
Sample name: Amlodipine Tablets IP 5 mg
Sample appearance: Orange round biconvex film coated tablet, plain on both sides
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 54 | Medicine: Amlodipine | Source: KMSCL | Batch No: ADFT1245 | Exp : Apr.26

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 18/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP-2022	Complies	-	-	-
3	Average weight		109.7	mg	-	-
4	Dissolution		87.6 to 92.3	%	5 mg	Q. Not less than 75
5	Uniformity of content		94.7 to 102.7	%		85.0 to 115.0
6	Related Substances					
	Amlodipine impurity D	IP-2022	Not detected	%	5 mg	Not more than 0.5
	Sum of all other secondary Impurities		Not detected	%		Not more than 0.5
7	Assay: Each film coated tablet contains					
	Amlodipine Besylate Eq. to Amlodipine	IP-2022	4.82 mg (i.e. 96.4 %)	mg	5 mg	4.50 mg to 5.50 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050141-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01965
Sample name: Amlodipine Tablets IP 5 mg
Sample appearance: White round flat uncoated tablet, scored on one side and plain on other side
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 55 | Medicine: Amlodipine | Source: DAVA | Batch No: ALDV5021 | Exp : Aug.27

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 18/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP-2022	Complies	-	-	-
3	Average weight		141.1	mg	-	-
4	Dissolution		89.2 to 94.6	%	5 mg	Q. Not less than 75
5	Uniformity of content		95.9 to 101.8	%		85.0 to 115.0
6	Related Substances					
	Amlodipine impurity D	IP-2022	Not detected	%	5 mg	Not more than 0.5
	Sum of all other secondary Impurities		Not detected	%		Not more than 0.5
7	Assay: Each uncoated tablet contains					
	Amlodipine Besilate Eq. to Amlodipine	IP-2022	4.84 mg (i.e. 96.8 %)	mg	5 mg	9.0 mg to 11.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050142-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01966
Sample name: Amlopres-5 (Amlodipine Tablets IP 5 mg)
Sample appearance: White round flat uncoated tablet, scored on one side and having inscribed "AP" on other side
Sample quantity: 42 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 56 | Medicine: Amlodipine | Source: BGENERIC | Batch No: 5SN1194 | Exp : Apr.28

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 18/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP-2022	Complies	-	-	-
3	Average weight		121.42	mg	-	-
4	Dissolution		95.6 to 102.1	%	5 mg	Q. Not less than 75
5	Uniformity of content		96.2 to 103.5	%		85.0 to 115.0
6	Related Substances					
	Amlodipine impurity D	IP-2022	Not detected	%	5 mg	Not more than 0.5
	Sum of all other secondary Impurities		Not detected	%		Not more than 0.5
7	Assay: Each uncoated tablet contains					
	Amlodipine Besilate Eq. to Amlodipine	IP-2022	5.04 mg (i.e. 100.8 %)	mg	5 mg	9.0 mg to 11.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050143-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01967
Sample name: Avacard-5 (Amlodipine Besilate Tablets IP 5 mg)
Sample appearance: White round flat uncoated tablet, scored on one side and plain on other side
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 57 | Medicine: Amlodipine | Source: BGENERIC | Batch No: LAC0047 | Exp : Jun.27

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 18/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP-2022	Complies	-	-	-
3	Average weight		112.3	mg	-	-
4	Dissolution		97.1 to 103.5	%	5 mg	Q. Not less than 75
5	Uniformity of content		95.7 to 102.6	%		85.0 to 115.0
6	Related Substances					
	Amlodipine impurity D	IP-2022	Not detected	%	5 mg	Not more than 0.5
	Sum of all other secondary Impurities		Not detected	%		Not more than 0.5
7	Assay: Each uncoated tablet contains					
	Amlodipine Besilate Eq. to Amlodipine	IP-2022	5.02 mg (i.e. 100.4 %)	mg	5 mg	9.0 mg to 11.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050144-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01968
Sample name: Amlovas-5 (Amlodipine Besilate Tablets IP)
Sample appearance: White round biconvex uncoated tablet, having inscribed “A 5” on scored side and plain on other side
Sample quantity: 45 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 58 | Medicine: Amlodipine | Source: BRAND | Batch No: TAB2401A | Exp : Jun.28

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 18/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP-2022	Complies	-	-	-
3	Average weight		134.5	mg	-	-
4	Dissolution		97.6 to 104.1	%	5 mg	Q. Not less than 75
5	Uniformity of content		94.5 to 102.9	%		85.0 to 115.0
6	Related Substances					
	Amlodipine impurity D	IP-2022	Not detected	%	5 mg	Not more than 0.5
	Sum of all other secondary Impurities		Not detected	%		Not more than 0.5
7	Assay: Each uncoated tablet contains					
	Amlodipine Besilate Eq. to Amlodipine	IP-2022	5.05 mg (i.e. 101.0 %)	mg	5 mg	9.0 mg to 11.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050145-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01969
Sample name: Amlogard-5 mg (Amlodipine Besilate Tablets IP)
Sample appearance: White round biconvex uncoated tablet, having inscribed “AML 5” on one side and scored on other side
Sample quantity: 42 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 59 | Medicine: Amlodipine | Source: BRAND | Batch No: EMV251701 | Exp : Jun.28

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 18/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP-2022	Complies	-	-	-
3	Average weight		201.7	mg	-	-
4	Dissolution		92.1 to 98.4	%	5 mg	Q. Not less than 75
5	Uniformity of content		93.4 to 103.4	%		85.0 to 115.0
6	Related Substances					
	Amlodipine impurity D	IP-2022	Not detected	%	5 mg	NMT 0.5
	Sum of all other secondary Impurities		Not detected	%		NMT 0.5
7	Assay: Each uncoated tablet contains					
	Amlodipine Besilate Eq. to Amlodipine	IP-2022	4.92 mg (i.e. 98.4 %)	mg	5 mg	9.0 mg to 11.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050147-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01970
Sample name: Telmisartan Tablets IP 40 mg
Sample appearance: Off white round biconvex uncoated tablet, plain on both sides
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 60 | Medicine: Telmisartan | Source: JAUSH | Batch No: TEP25110AL | Exp : Mar.27

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 18/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP-2022	Complies	-	-	-
3	Average weight		228.8	mg	-	-
4	Uniformity of weight		-1.7 to + 2.4	%	-	± 7.5
5	Dissolution		93.5 to 97.6	%	40 mg	Q. Not less than 75
6	Related Substances					
	Any secondary impurity	IP-2022	Not detected	%	40 mg	Not more than 0.5
	Total secondary Impurities		Not detected	%		Not more than 2.0
7	Assay: Each uncoated tablet contains					
	Telmisartan	IP-2022	38.9 mg (i.e. 97.3 %)	mg	40 mg	36.0 mg to 44.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050148-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01971
Sample name: Telmitron-40 (Telmisartan Tablets IP)
Sample appearance: Off white round biconvex uncoated tablet, plain on both sides
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 61 | Medicine: Telmisartan | Source: GENERIC | Batch No: GT250631 | Exp : Feb.27

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 18/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP-2022	Complies	-	-	-
3	Average weight		268.8	mg	-	-
4	Uniformity of weight		-1.2 to + 2.1	%	-	± 5.0
5	Dissolution		90.7 to 96.8	%	40 mg	Q. Not less than 75
6	Related Substances					
	Any secondary impurity	IP-2022	Not detected	%	40 mg	Not more than 0.5
	Total secondary Impurities		Not detected	%		Not more than 2.0
7	Assay: Each uncoated tablet contains					
	Telmisartan	IP-2022	39.1 mg (i.e. 97.8 %)	mg	40 mg	36.0 mg to 44.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050149-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01972
Sample name: Telmates 40 (Telmisartan Tablets IP 40 mg)
Sample appearance: Off white round biconvex uncoated tablet, plain on both sides
Sample quantity: 45 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 18/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

Customer provided details: S.R No : 62 | Medicine: Telmisartan | Source: GENERIC | Batch No: TAS25004 | Exp : Jul.28

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP-2022	Complies	-	-	-
3	Average weight		178.6	mg	-	-
4	Uniformity of weight		-2.8 to + 1.5	%	-	± 7.5
5	Dissolution		91.7 to 96.5	%	40 mg	Q. Not less than 75
6	Related Substances					
	Any secondary impurity	IP-2022	Not detected	%	40 mg	Not more than 0.5
	Total secondary Impurities		Not detected	%		Not more than 2.0
7	Assay: Each uncoated tablet contains					
	Telmisartan	IP-2022	38.3 mg (i.e. 95.8 %)	mg	40 mg	36.0 mg to 44.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050150-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01973
Sample name: Telmiget-40 (Telmisartan Tablets IP 40 mg)
Sample appearance: Off white round flat uncoated tablet, scored on one side and plain on other side
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 18/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

Customer provided details: S.R No : 63 | Medicine: Telmisartan | Source: BGENERIC | Batch No: LE125032 | Exp : May.27

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP-2022	Complies	-	-	-
3	Average weight		239.8	mg	-	-
4	Uniformity of weight		-1.9 to + 1.4	%	-	± 7.5
5	Dissolution		92.7 to 98.5	%	40 mg	Q. Not less than 75
6	Related Substances					
	Any secondary impurity	IP-2022	Not detected	%	40 mg	Not more than 0.5
	Total secondary Impurities		Not detected	%		Not more than 2.0
7	Assay: Each uncoated tablet contains					
	Telmisartan	IP-2022	39.1 mg (i.e. 97.8 %)	mg	40 mg	36.0 mg to 44.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050151-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01974
Sample name: Telvas 40 (Telmisartan Tablets IP 40 mg)
Sample appearance: White round flat uncoated tablet, scored on one side and plain on other side
Sample quantity: 45 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 18/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

Customer provided details: S.R No : 64 | Medicine: Telmisartan | Source: BGENERIC | Batch No: SPD250495 | Exp : Mar.27

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP-2022	Complies	-	-	-
3	Average weight		251.9	mg	-	-
4	Uniformity of weight		-2.2 to + 1.7	%	-	± 5.0
5	Dissolution		97.6 to 102.2	%	40 mg	Q. Not less than 75
6	Related Substances					
	Any secondary impurity	IP-2022	Not detected	%	40 mg	Not more than 0.5
	Total secondary Impurities		Not detected	%		Not more than 2.0
7	Assay: Each uncoated tablet contains					
	Telmisartan	IP-2022	40.5 mg (i.e. 101.3 %)	mg	40 mg	36.0 mg to 44.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050152-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01975
Sample name: TAZLOC-40 (Telmisartan Tablets IP 40 mg)
Sample appearance: White round biconvex uncoated tablet, plain on both sides
Sample quantity: 45 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 18/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

Customer provided details: S.R No : 65 | Medicine: Telmisartan | Source: BRAND | Batch No: 48020294 | Exp : Apr.27

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP-2022	Complies	-	-	-
3	Average weight		260.7	mg	-	-
4	Uniformity of weight		-1.9 to + 1.3	%	-	± 5.0
5	Dissolution		94.3 to 101.7	%	40 mg	Q. Not less than 75
6	Related Substances					
	Any secondary impurity	IP-2022	Not detected	%	40 mg	Not more than 0.5
	Total secondary Impurities		Not detected	%		Not more than 2.0
7	Assay: Each uncoated tablet contains					
	Telmisartan	IP-2022	40.3 mg (i.e.100.8 %)	mg	40 mg	36.0 mg to 44.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050315-02
Report date: 28/01/2026

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01958
Sample name: Metformin hydrochloride Sustained Release Tablets IP 500 mg
Sample appearance: White round flat uncoated sustained release tablet, scored on one, plain on other side
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 41 | Medicine: Metformin | Source: KMSCL | Batch No: MTTJ25097 | Exp : Jun.27

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 28/01/2026
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		628.5	mg	-	-
4	Uniformity of weight		-1.6 to + 1.2	%	-	± 5.0
5	Dissolution					
	For 1 hour	IP-2022	21.4 to 24.6	%	500 mg	For information only
	For 3 hours		50.6 to 55.6	%		
	For 10 hours		93.8 to 96.7	%		
5	Related substances					
	Dicyandiamide	IP-2022	Not detected	%	500 mg	Not more than 0.02
	Any other secondary impurity		Not detected	%		Not more than 0.1
6	Assay: Each uncoated sustained release tablet contains					

	Metformin hydrochloride	IP- 2022	490.7 mg (i.e. 98.1 %)	mg	500 mg	450.0 mg to 550.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

This report supersedes the report number: TR-25-EKA2- 050315-01 dated 28/12/2025" Dissolution parameters updated as per client requirement and previous version stands cancelled

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050317-02
Report date: 28/01/2026

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01960
Sample name: MetGem 500 (Metformin hydrochloride Extended-Release Tablets IP)
Sample appearance: White oval shaped biconvex uncoated extended release tablet, plain on both sides
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 43 | Medicine: Metformin | Source: BGENERIC | Batch No: SIG0821B | Exp : Mar.27

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 28/01/2026
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		660.5	mg	-	-
4	Uniformity of weight		-0.9 to + 1.3	%	-	± 5.0
5	Dissolution					
	For 1 hour	IP-2022	20.2 to 25.3	%	500 mg	For information only
	For 3 hours		52.3 to 57.4	%		
	For 10 hours		94.7 to 97.3	%		
5	Related substances					
	Dicyandiamide	IP-2022	Not detected	%	500 mg	Not more than 0.02
	Any other secondary impurity		Not detected	%		Not more than 0.1
6	Assay: Each uncoated extended release tablet contains					

	Metformin hydrochloride	IP- 2022	496.3 mg (i.e. 99.3 %)	mg	500 mg	450.0 mg to 550.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

This report supersedes the report number: TR-25-EKA2- 050317-01 dated 28/12/2025" Dissolution parameters updated as per client requirement and previous version stands cancelled

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050153-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01976
Sample name: TELSAR 40 (Telmisartan Tablets IP)
Sample appearance: White round biconvex uncoated tablet, scored on one side and plain on other side
Sample quantity: 45 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 66 | Medicine: Telmisartan | Source: BRAND | Batch No: 2MJ3M012 | Exp : Jun.28

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 18/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP-2022	Complies	-	-	-
3	Average weight		240.8	mg	-	-
4	Uniformity of weight		-1.7 to + 2.1	%	-	± 7.5
5	Dissolution		96.7 to 102.8	%	40 mg	Q. Not less than 75
6	Related Substances					
	Any secondary impurity	IP-2022	Not detected	%	40 mg	Not more than 0.5
	Total secondary Impurities		Not detected	%		Not more than 2.0
7	Assay: Each uncoated tablet contains					
	Telmisartan	IP-2022	40.8 mg (i.e. 102.0 %)	mg	40 mg	36.0 mg to 44.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050154-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01977
Sample name: Montelukast Tablets IP 10 mg
Sample appearance: Light yellow coloured round shaped biconvex film coated tablet, plain on both sides
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 67 | Medicine: Montelukast | Source: JAUSH | Batch No: BP5149 | Exp : Apr.27

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 23/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP-2022	Complies	-	-	-
3	Average weight		104.2	mg	-	-
4	Dissolution		83.9 to 88.9	%	10 mg	Q. Not less than 70
5	Uniformity of content		95.1 to 101.4	%		85.0 to 115.0
6	Related Substances					
	Sulphoxide impurity	IP-2022	Not detected	%	10 mg	Not more than 1.0
	Styrene impurity		Not detected	%		Not more than 0.5
	Any other secondary Impurity		Not detected	%		Not more than 0.5
	Sum of all the secondary Impurities		Not detected	%		Not more than 2.0
7	Assay: Each film coated tablet contains					
	Montelukast sodium	IP-2022	9.65 mg	mg	10 mg	9.0 mg to 11.0 mg

	Equivalent to Montelukast		(i.e. 96.5 %)			(i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050155-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01978

Sample name: SWASMONT-10 (Montelukast Sodium Tablets IP 10 mg)

Sample appearance: Whight round shaped biconvex film coated tablet, plain on both sides

Sample quantity: 45 Nos

Condition on receipt: Good

Sample packing: Sealed Pack

Environmental condition: Not Applicable

Customer provided details: S.R No : 68 | Medicine: Montelukast | Source: GENADH | Batch No: 169DK01 | Exp : Apr.26

Sample receipt date: 12/12/2025

Analysed between: 12/12/2025 to 23/12/2025

Sampling details: Not Sampled by Eureka

Sample seal no.: Not Applicable

Sampling procedure: Not Applicable

Sampling date: Not Applicable

Sampling location: Not Applicable

Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP-2022	Complies	-	-	-
3	Average weight		160.5	mg	-	-
4	Dissolution		90.8 to 94.9	%	10 mg	Q. Not less than 70
5	Uniformity of content		93.7 to 102.5	%		85.0 to 115.0
6	Related Substances					
	Sulphoxide impurity	IP-2022	Not detected	%	10 mg	Not more than 1.0
	Styrene impurity		Not detected	%		Not more than 0.5
	Any other secondary Impurity		Not detected	%		Not more than 0.5
	Sum of all the secondary Impurities		Not detected	%		Not more than 2.0
7	Assay: Each film coated tablet contains					

	Montelukast sodium Eq. to Montelukast	IP-2022	9.71 mg (i.e. 97.1 %)	mg	10 mg	9.0 mg to 11.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050156-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01979
Sample name: Montelukast Sodium Tablets IP 10 mg
Sample appearance: Yellow coloured round shaped biconvex film coated tablet, plain on both sides
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 69 | Medicine: Montelukast | Source: DAVA | Batch No: SPT251461 | Exp : May.27

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 23/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP-2022	Complies	-	-	-
3	Average weight		137.1	mg	-	-
4	Dissolution		88.2 to 93.6	%	10 mg	Q. Not less than 70
5	Uniformity of content		94.7 to 102.7	%		85.0 to 115.0
6	Related Substances					
	Sulphoxide impurity	IP-2022	Not detected	%	10 mg	Not more than 1.0
	Styrene impurity		Not detected	%		Not more than 0.5
	Any other secondary Impurity		Not detected	%		Not more than 0.5
	Sum of all the secondary Impurities		Not detected	%		Not more than 2.0
7	Assay: Each film coated tablet contains					
	Montelukast sodium	IP-2022	9.74 mg	mg	10 mg	9.0 mg to 11.0 mg

	Eq. to Montelukast		(i.e. 97.4 %)			(i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050157-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01980
Sample name: Minolast-10 (Montelukast Sodium Tablets IP 10 mg)
Sample appearance: Yellow coloured round shaped biconvex film coated tablet, plain on both sides
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 70 | Medicine: Montelukast | Source: BGENERIC | Batch No: 6005001 | Exp : Feb.27

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 23/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP-2022	Complies	-	-	-
3	Average weight		104.3	mg	-	-
4	Dissolution		87.5 to 94.6	%	10 mg	Q. Not less than 70
5	Uniformity of content		96.7 to 102.8	%		85.0 to 115.0
6	Related Substances					
	Sulphoxide impurity	IP-2022	Not detected	%	10 mg	Not more than 1.0
	Styrene impurity		Not detected	%		Not more than 0.5
	Any other secondary Impurity		Not detected	%		Not more than 0.5
	Sum of all the secondary Impurities		Not detected	%		Not more than 2.0
7	Assay: Each film coated tablet contains					
	Montelukast sodium	IP-2022	9.83 mg	mg	10 mg	9.0 mg to 11.0 mg

	Eq. to Montelukast		(i.e. 98.3 %)			(i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050158-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01981
Sample name: Telekast-10 (Montelukast Tablets IP)
Sample appearance: Light orange coloured round shaped biconvex film coated tablet, plain on both sides
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 71 | Medicine: Montelukast | Source: BRAND| Batch No: UB00304 | Exp : Dec.26

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 23/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP-2022	Complies	-	-	-
3	Average weight		185.8	mg	-	-
4	Dissolution		96.3 to 102.7	%	10 mg	Q. Not less than 70
5	Uniformity of content		97.5 to 102.9	%		85.0 to 115.0
6	Related Substances					
	Sulphoxide impurity	IP-2022	Not detected	%	10 mg	Not more than 1.0
	Styrene impurity		Not detected	%		Not more than 0.5
	Any other secondary Impurity		Not detected	%		Not more than 0.5
	Sum of all the secondary Impurities		Not detected	%		Not more than 2.0
7	Assay: Each film coated tablet contains					
	Montelukast sodium	IP-2022	10.18 mg	mg	10 mg	9.0 mg to 11.0 mg

	Equivalent to Montelukast		(i.e. 101.8 %)			(i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050159-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01982
Sample name: Montek 10 (Montelukast Tablets IP)
Sample appearance: Orange coloured round shaped biconvex film coated tablet, scored on one side and plain on other side
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 72 | Medicine: Montelukast | Source: BRAND| Batch No: GTG1010A | Exp : Mar.27

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 23/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP-2022	Complies	-	-	-
3	Average weight		146.7	mg	-	-
4	Dissolution		97.6 to 103.5	%	10 mg	Q. Not less than 70
5	Uniformity of content		97.5 to 102.2	%		85.0 to 115.0
6	Related Substances					
	Sulphoxide impurity	IP-2022	Not detected	%	10 mg	Not more than 1.0
	Styrene impurity		Not detected	%		Not more than 0.5
	Any other secondary Impurity		Not detected	%		Not more than 0.5
	Sum of all the secondary Impurities		Not detected	%		Not more than 2.0
7	Assay: Each film coated tablet contains					
	Montelukast sodium	IP-2022	10.27 mg	mg	10 mg	9.0 mg to 11.0 mg

	Equivalent to Montelukast		(i.e.102.7 %)			(i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050160-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01983
Sample name: Ibuprofen Tablets IP 400 mg
Sample appearance: Pink coloured elongated shaped biconvex film coated tablet, scored on one side and plain on other side
Sample quantity: 45 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 20/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

Customer provided details: S.R No : 73 | Medicine: Ibuprofen | Source: JAUSH | Batch No: IBBT1231 | Exp : Sep.26

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		524.8	mg	-	-
4	Uniformity of weight		-1.2 to + 1.4	%	-	± 5.0
5	Dissolution		93.8 to 98.9	%	400 mg	Q. Not less than 75
6	Related substances		Complies	-		-
7	Assay: Each film coated tablet contains					
	Ibuprofen	IP- 2022	389.2 mg (i.e. 97.3 %)	mg	400 mg	380.0 mg to 420.0 mg (i.e. 95.0 % to 105.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050161-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01984
Sample name: Ibuprofen Tablets IP 400 mg
Sample appearance: Dark pink coloured round shaped biconvex film coated tablet, plain on both sides
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 74 | Medicine: Ibuprofen | Source: GENERIC | Batch No: IBF-2402 | Exp : Apr.27

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 20/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		580.2	mg	-	-
4	Uniformity of weight		-1.1 to + 0.9	%	-	± 5.0
5	Dissolution		95.2 to 101.5	%	400 mg	Q. Not less than 75
6	Related substances		Complies	-		-
7	Assay: Each film coated tablet contains					
	Ibuprofen	IP- 2022	393.5 mg (i.e. 98.4 %)	mg	400 mg	380.0 mg to 420.0 mg (i.e. 95.0 % to 105.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050162-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01985
Sample name: Brufen 400 (Ibuprofen Tablets IP)
Sample appearance: Dark pink coloured round shaped biconvex film coated tablet, plain on both sides
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 75 | Medicine: Ibuprofen | Source: BRAND | Batch No: 802807D7 | Exp : Jul.28

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 20/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		568.2	mg	-	-
4	Uniformity of weight		-0.8 to + 1.3	%	-	± 5.0
5	Dissolution		96.1 to 102.6	%	400 mg	Q. Not less than 75
6	Related substances		Complies	-		-
7	Assay: Each film coated tablet contains					
	Ibuprofen	IP- 2022	403.7 mg (i.e. 100.9 %)	mg	400 mg	380.0 mg to 420.0 mg (i.e. 95.0 % to 105.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050163-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01986
Sample name: Thyroxine Sodium Tablets IP 100 mcg
Sample appearance: White round shaped biconvex uncoated tablet, plain on both sides
Sample quantity: 100 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 76 | Medicine: Thyroxine Sodium | Source: JAUSH | Batch No: 15525 | Exp : Jan.26

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 22/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP-2022	Complies	-	-	-
3	Average weight		140.1	mg	-	-
4	Dissolution		91.4 to 95.6	%	100 mcg	Q. Not less than 70
5	Liothyronine Sodium		Complies	-		-
6	Uniformity of content		94.7 to 102.5	%		85.0 to 115.0
7	Assay: Each uncoated tablet contains					
	Thyroxine Sodium Equivalent to anhydrous Thyroxine Sodium	IP-2022	96.8 mcg (i.e. 96.8 %)	mcg	100 mcg	90.0 mcg to 110.0 mcg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050164-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01987
Sample name: Thyroxine Sodium Tablets IP 100 mcg
Sample appearance: Light yellow coloured round shaped biconvex uncoated tablet, plain on both sides
Sample quantity: 100 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 77 | Medicine: Thyroxine Sodium | Source: KMSCL | Batch No: BGL02ACA | Exp : Jul.27

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 22/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP-2022	Complies	-	-	-
3	Average weight		101.9	mg	-	-
4	Dissolution		92.8 to 97.9	%	100 mcg	Q. Not less than 70
5	Liothyronine Sodium		Complies	-		-
6	Uniformity of content		95.3 to 103.8	%		85.0 to 115.0
7	Assay: Each uncoated tablet contains					
	Thyroxine Sodium Eq. to anhydrous Thyroxine Sodium	IP-2022	97.7 mcg (i.e. 97.7 %)	mcg	100 mcg	90.0 mcg to 110.0 mcg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050165-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH), Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01988

Sample name: Thyrosun 100 (Thyroxine Sodium Tablets IP 100 mcg)

Sample appearance: White round shaped biconvex uncoated tablet, plain on both sides

Sample quantity: 120 Nos

Condition on receipt: Good

Sample packing: Sealed Pack

Environmental condition: Not Applicable

Customer provided details: S.R No : 78 | Medicine: Thyroxine Sodium | Source: BGENERIC | Batch No: MHT-25038 | Exp : Jan.27

Sample receipt date: 12/12/2025

Analysed between: 12/12/2025 to 22/12/2025

Sampling details: Not Sampled by Eureka

Sample seal no.: Not Applicable

Sampling procedure: Not Applicable

Sampling date: Not Applicable

Sampling location: Not Applicable

Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP-2022	Complies	-	-	-
3	Average weight		121.1	mg	-	-
4	Dissolution		95.5 to 102.3	%	100 mcg	Q. Not less than 70
5	Liothyronine Sodium		Complies	-		-
6	Uniformity of content		95.2 to 101.9	%		85.0 to 115.0
7	Assay: Each uncoated tablet contains					
	Thyroxine Sodium Equivalent to anhydrous Thyroxine Sodium	IP-2022	102.4 mcg (i.e. 102.4 %)	mcg	100 mcg	90.0 mcg to 110.0 mcg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050166-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01989
Sample name: Thyronorm 100 mcg (Thyroxine Sodium Tablets IP)
Sample appearance: Light yellow coloured round shaped biconvex uncoated tablet, having inscribed “100” on one side and plain on other side
Sample quantity: 120 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 79 | Medicine: Thyroxine Sodium | Source: BRAND | Batch No: TMH25174 | Exp : Jul.27

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 22/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP-2022	Complies	-	-	-
3	Average weight		102.4	mg	-	-
4	Dissolution		96.8 to 103.7	%	100 mcg	Q. Not less than 70
5	Liothyronine Sodium		Complies	-		-
6	Uniformity of content		96.2 to 102.1	%		85.0 to 115.0
7	Assay: Each uncoated tablet contains					
	Thyroxine Sodium Equivalent to anhydrous Thyroxine Sodium	IP-2022	102.8 mcg (i.e. 102.8 %)	mcg	100 mcg	90.0 mcg to 110.0 mcg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050167-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01990

Sample name: ELTROXIN Tablets (Thyroxine Sodium Tablets IP 100 mcg)

Sample appearance: White round shaped biconvex uncoated tablet, having inscribed “A” on one side and scored on other side

Sample quantity: 120 Nos

Condition on receipt: Good

Sample packing: Sealed Pack

Environmental condition: Not Applicable

Customer provided details: S.R No : 80 | Medicine: Thyroxine Sodium | Source: BRAND | Batch No: GA7N | Exp : Oct.26

Sample receipt date: 12/12/2025

Analysed between: 12/12/2025 to 22/12/2025

Sampling details: Not Sampled by Eureka

Sample seal no.: Not Applicable

Sampling procedure: Not Applicable

Sampling date: Not Applicable

Sampling location: Not Applicable

Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP-2022	Complies	-	-	-
3	Average weight		150.8	mg	-	-
4	Dissolution		96.2 to 103.2	%	100 mcg	Q. Not less than 70
5	Liothyronine Sodium		Complies	-		-
6	Uniformity of content		95.9 to 101.9	%		85.0 to 115.0
7	Assay: Each uncoated tablet contains					
	Thyroxine Sodium (as anhydrous)	IP-2022	102.5 mcg (i.e. 102.5 %)	mcg	100 mcg	90.0 mcg to 110.0 mcg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050168-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01991
Sample name: Cetirizine Tablets IP 10 mg
Sample appearance: White elongated biconvex film coated tablets, scored on side and plain on other side
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 15/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

Customer provided details: S.R No : 81 | Medicine: Cetrizine | Source: JAUSH | Batch No: Z25-371 | Exp : Mar.27

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description		Complies	-	-	-
2	Identification	IP-2022	Complies	-	-	-
3	Average weight		137.8	mg	-	-
4	Dissolution		85.6 to 90.3	%	10 mg	Q. Not less than 75
5	Uniformity of content		95.6 to 102.5	%		85.0 to 115.0
6	Related Substances					
	Any secondary Impurity	IP-2022	Not detected	%	10 mg	Not more than 0.5
	Sum of all the secondary Impurities		Not detected	%		Not more than 1.0
7	Assay: Each film coated tablet contains					
	Cetirizine hydrochloride	IP-2022	9.65 mg (i.e. 96.5 %)	mg	10 mg	9.00 mg to 11.00 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050169-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01992
Sample name: Swascetri (Cetirizine Tablets IP 10 mg)
Sample appearance: White elongated biconvex film coated tablets, scored on side and plain on other side
Sample quantity: 45 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 15/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

Customer provided details: S.R No : 82 | Medicine: Cetrizine | Source: GENADH | Batch No: M25639001 | Exp : Apr.27

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description		Complies	-	-	-
2	Identification	IP-2022	Complies	-	-	-
3	Average weight		132.6	mg	-	-
4	Dissolution		89.7 to 92.5	%	10 mg	Q. Not less than 75
5	Uniformity of content		96.6 to 103.3	%		85.0 to 115.0
6	Related Substances					
	Any secondary Impurity	IP-2022	Not detected	%	10 mg	Not more than 0.5
	Sum of all the secondary Impurities		Not detected	%		Not more than 1.0
7	Assay: Each film coated tablet contains					
	Cetirizine hydrochloride	IP-2022	9.71 mg (i.e. 97.1 %)	mg	10 mg	9.00 mg to 11.00 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050170-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01993
Sample name: Cetirizine Hydrochloride Tablets IP 10 mg
Sample appearance: White elongated biconvex film coated tablets, scored on side and plain on other side
Sample quantity: 45 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 83 | Medicine: Cetrizine | Source: DAVA | Batch No: AT-25021 | Exp : Mar.27

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 15/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP-2022	Complies	-	-	-
3	Average weight		120.5	mg	-	-
4	Dissolution		91.3 to 95.8	%	10 mg	Q. Not less than 75
5	Uniformity of content		95.7 to 102.8	%		85.0 to 115.0
6	Related Substances					
	Any secondary Impurity	IP-2022	Not detected	%	10 mg	Not more than 0.5
	Sum of all the secondary Impurities		Not detected	%		Not more than 1.0
7	Assay: Each film coated tablet contains					
	Cetirizine hydrochloride	IP-2022	9.68 mg (i.e. 96.8 %)	mg	10 mg	9.00 mg to 11.00 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050171-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01994
Sample name: Zedcet (Cetirizine Hydrochloride Tablets IP 10 mg)
Sample appearance: White elongated biconvex film coated tablets, scored on side and plain on other side
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 84 | Medicine: Cetrizine | Source: BGENERIC | Batch No: SBT-3070 | Exp : Mar.27

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 15/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP-2022	Complies	-	-	-
3	Average weight		173.5	mg	-	-
4	Dissolution		88.1 to 94.6	%	10 mg	Q. Not less than 75
5	Uniformity of content		94.7 to 102.8	%		85.0 to 115.0
6	Related Substances					
	Any secondary Impurity	IP-2022	Not detected	%	10 mg	Not more than 0.5
	Sum of all the secondary Impurities		Not detected	%		Not more than 1.0
7	Assay: Each film coated tablet contains					
	Cetirizine hydrochloride	IP-2022	9.88 mg (i.e. 98.8 %)	mg	10 mg	9.00 mg to 11.00 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050172-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01995
Sample name: Okacet (Cetirizine Hydrochloride Tablets IP 10 mg)
Sample appearance: White elongated biconvex film coated tablets, scored on side and plain on other side
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 85 | Medicine: Cetrizine | Source: BGENERIC | Batch No: 5B50236 | Exp : Jan.28

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 15/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP-2022	Complies	-	-	-
3	Average weight		124.4	mg	-	-
4	Dissolution		94.8 to 101.2	%	10 mg	Q. Not less than 75
5	Uniformity of content		96.3 to 101.9	%		85.0 to 115.0
6	Related Substances					
	Any secondary Impurity	IP-2022	Not detected	%	10 mg	Not more than 0.5
	Sum of all the secondary Impurities		Not detected	%		Not more than 1.0
7	Assay: Each film coated tablet contains					
	Cetirizine hydrochloride	IP-2022	10.12 mg (i.e. 101.2 %)	mg	10 mg	9.00 mg to 11.00 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050173-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01996
Sample name: Cetzine (Cetirizine Hydrochloride Tablets IP 10 mg)
Sample appearance: White elongated biconvex film coated tablets, scored on side and plain on other side
Sample quantity: 45 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 86 | Medicine: Cetrizine | Source: BRAND | Batch No: EMV251660 | Exp : Jun.28

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 15/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP-2022	Complies	-	-	-
3	Average weight		117.6	mg	-	-
4	Dissolution		96.2 to 100.8	%	10 mg	Q. Not less than 75
5	Uniformity of content		95.8 to 102.6	%		85.0 to 115.0
6	Related Substances					
	Any secondary Impurity	IP-2022	Not detected	%	10 mg	Not more than 0.5
	Sum of all the secondary Impurities		Not detected	%		Not more than 1.0
7	Assay: Each film coated tablet contains					
	Cetirizine hydrochloride	IP-2022	9.92 mg (i.e. 99.2 %)	mg	10 mg	9.00 mg to 11.00 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050174-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01997
Sample name: Alerid (Cetirizine Hydrochloride Tablets IP 10 mg)
Sample appearance: White round biconvex film coated tablets, having inscribed "A" on side and scored on other side
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 87 | Medicine: Cetrizine | Source: BRAND | Batch No: 5SB0392 | Exp : Mar.28

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 15/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP-2022	Complies	-	-	-
3	Average weight		185.3	mg	-	-
4	Dissolution		97.2 to 101.2	%	10 mg	Q. Not less than 75
5	Uniformity of content		95.2 to 102.1	%		85.0 to 115.0
6	Related Substances					
	Any secondary Impurity	IP-2022	Not detected	%	10 mg	Not more than 0.5
	Sum of all the secondary Impurities		Not detected	%		Not more than 1.0
7	Assay: Each film coated tablet contains					
	Cetirizine hydrochloride	IP-2022	10.22 mg (i.e. 102.2 %)	mg	10 mg	9.00 mg to 11.00 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050320-01
Report date: 28/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01998
Sample name: Clopidogrel Tablets IP 75 mg
Sample appearance: Marron coloured round shaped biconvex film coated tablet, plain on both sides
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 88 | Medicine: Clopidogrel | Source: JAUSH | Batch No: CT 24251296 | Exp : Sep.26

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 26/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP- 2022	Complies	-	-	-
3	Average weight		310.3	mg	-	-
4	Uniformity of weight		-1.4 to +1.8	%	75 mg	±5
5	Dissolution		91.3 to 97.4	%		Q. Not less than 80
6	Related Substances					
	Clopidogrel impurity A	IP- 2022	Not detected	%	75 mg	Not more than 1.2
	Clopidogrel impurity C		Not detected	%		Not more than 1.5
	Any other impurities excluding impurity B		Not detected	%		Not more than 0.2
	Total impurities excluding impurity B		Not detected	%		Not more than 2.5
7	Assay: Each film coated tablet contains					
	Clopidogrel Bisulphate	IP- 2022	73.8 mg	mg	75 mg	67.5 mg to 82.5 mg

	Eq. to Clopidogrel		(i.e. 98.4 %)			(i.e. 90.0 to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050321-01
Report date: 28/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-01999
Sample name: CLOPIPAL-75 (Clopidogrel Bisulphate Tablets IP)
Sample appearance: Light pink coloured round shaped biconvex film coated tablet, plain on both sides
Sample quantity: 45 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 89 | Medicine: Clopidogrel | Source: GENERIC | Batch No: JD25056 | Exp : Mar.27

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 26/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP- 2022	Complies	-	-	-
3	Average weight		177.9	mg	-	-
4	Uniformity of weight		-1.9 to +2.2	%	75 mg	±7.5
5	Dissolution		94.5 to 99.2	%		Q. Not less than 80
6	Related Substances					
	Clopidogrel impurity A	IP- 2022	Not detected	%	75 mg	Not more than 1.2
	Clopidogrel impurity C		Not detected	%		Not more than 1.5
	Any other impurities excluding impurity B		Not detected	%		Not more than 0.2
	Total impurities excluding impurity B		Not detected	%		Not more than 2.5
7	Assay: Each film coated tablet contains					
	Clopidogrel Bisulphate	IP- 2022	75.3 mg	mg	75 mg	67.5 mg to 82.5 mg

	Equivalent. to Clopidogrel		(i.e. 100.4 %)			(i.e. 90.0 to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050322-01
Report date: 28/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02000
Sample name: Clopidogrel Tablets IP 75 mg
Sample appearance: Marron coloured round shaped biconvex film coated tablet, plain on both sides
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 90 | Medicine: Clopidogrel | Source: DAVA | Batch No: CKX02AAA | Exp : May.27

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 26/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP- 2022	Complies	-	-	-
3	Average weight		316.5	mg	-	-
4	Uniformity of weight		-1.2 to +1.9	%	75 mg	±5
5	Dissolution		93.7 to 96.5	%		Q. Not less than 80
6	Related Substances					
	Clopidogrel impurity A	IP- 2022	Not detected	%	75 mg	Not more than 1.2
	Clopidogrel impurity C		Not detected	%		Not more than 1.5
	Any other impurities excluding impurity B		Not detected	%		Not more than 0.2
	Total impurities excluding impurity B		Not detected	%		Not more than 2.5
7	Assay: Each film coated tablet contains					
	Clopidogrel Bisulphate	IP- 2022	73.4 mg	mg	75 mg	67.5 mg to 82.5 mg

	Eq. to Clopidogrel		(i.e. 97.9 %)			(i.e. 90.0 to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050323-01
Report date: 28/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02001
Sample name: Clopivas-75 (Clopidogrel Tablets IP)
Sample appearance: Light pink coloured round shaped biconvex film coated tablet, plain on both sides
Sample quantity: 45 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 91 | Medicine: Clopidogrel | Source: BGENERIC | Batch No: 5SN1330 | Exp : May.27

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 26/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP- 2022	Complies	-	-	-
3	Average weight		275.4	mg	-	-
4	Uniformity of weight		-1.1 to +1.7	%	75 mg	±5
5	Dissolution		97.8 to 102.5	%		Q. Not less than 80
6	Related Substances					
	Clopidogrel impurity A	IP- 2022	Not detected	%	75 mg	Not more than 1.2
	Clopidogrel impurity C		Not detected	%		Not more than 1.5
	Any other impurities excluding impurity B		Not detected	%		Not more than 0.2
	Total impurities excluding impurity B		Not detected	%		Not more than 2.5
7	Assay: Each film coated tablet contains					
	Clopidogrel Bisulphate	IP- 2022	76.3 mg	mg	75 mg	67.5 mg to 82.5 mg

	Equivalent to Clopidogrel		(i.e. 101.7 %)			(i.e. 90.0 to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050324-01
Report date: 28/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02002
Sample name: DEPLATT (Clopidogrel Tablets IP)
Sample appearance: Light pink coloured round shaped biconvex film coated tablet, plain on both sides
Sample quantity: 45 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 92 | Medicine: Clopidogrel | Source: BGENERIC | Batch No: CY32M007 | Exp : Jun.27

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 26/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP- 2022	Complies	-	-	-
3	Average weight		267.7	mg	-	-
4	Uniformity of weight		-0.9 to +1.3	%	75 mg	±5
5	Dissolution		97.9 to 103.2	%		Q. Not less than 80
6	Related Substances					
	Clopidogrel impurity A	IP- 2022	Not detected	%	75 mg	Not more than 1.2
	Clopidogrel impurity C		Not detected	%		Not more than 1.5
	Any other impurities excluding impurity B		Not detected	%		Not more than 0.2
	Total impurities excluding impurity B		Not detected	%		Not more than 2.5
7	Assay: Each film coated tablet contains					
	Clopidogrel Bisulphate	IP- 2022	77.1 mg	mg	75 mg	67.5 mg to 82.5 mg

	Equivalent to Clopidogrel		(i.e. 102.8 %)			(i.e. 90.0 to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050325-01
Report date: 28/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02003
Sample name: Clopilet (Clopidogrel Tablets IP)
Sample appearance: Light pink coloured round shaped biconvex film coated tablet, plain on both sides
Sample quantity: 45 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 93 | Medicine: Clopidogrel | Source: BRAND | Batch No: GTG1571A | Exp : May.27

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 26/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP- 2022	Complies	-	-	-
3	Average weight		145.1	mg	-	-
4	Uniformity of weight		-1.4 to +1.8	%	75 mg	±7.5
5	Dissolution		98.4 to 102.7	%		Q. Not less than 80
6	Related Substances					
	Clopidogrel impurity A	IP- 2022	Not detected	%	75 mg	Not more than 1.2
	Clopidogrel impurity C		Not detected	%		Not more than 1.5
	Any other impurities excluding impurity B		Not detected	%		Not more than 0.2
	Total impurities excluding impurity B		Not detected	%		Not more than 2.5
7	Assay: Each film coated tablet contains					
	Clopidogrel Bisulphate	IP- 2022	76.9 mg	mg	75 mg	67.5 mg to 82.5 mg

	Equivalent to Clopidogrel		(i.e. 102.5 %)			(i.e. 90.0 to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050326-01
Report date: 28/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02004
Sample name: Plavix (Clopidogrel Tablets IP)
Sample appearance: Light pink coloured round shaped biconvex film coated tablet, having logo one side and inscribed "75" on other side
Sample quantity: 42 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 94 | Medicine: Clopidogrel | Source: BRAND | Batch No: FA4064 | Exp : Aug.27

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 26/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP- 2022	Complies	-	-	-
3	Average weight		255.1	mg	-	-
4	Uniformity of weight		1.6 to 1.7	%	75 mg	±5
5	Dissolution		97.4 to 102.6	%		Q. Not less than 80
6	Related Substances					
	Clopidogrel impurity A	IP- 2022	Not detected	%	75 mg	Not more than 1.2
	Clopidogrel impurity C		Not detected	%		Not more than 1.5
	Any other impurities excluding impurity B		Not detected	%		Not more than 0.2
	Total impurities excluding impurity B		Not detected	%		Not more than 2.5
7	Assay: Each film coated tablet contains					

	Clopidogrel Bisulphate Equivalent to Clopidogrel	IP- 2022	76.2 mg (i.e.101.6 %)	mg	75 mg	67.5 mg to 82.5 mg (i.e. 90.0 to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050327-01
Report date: 28/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02005
Sample name: Aspirin Gastro-Resistant Tablets IP 75 mg
Sample appearance: White round shaped biconvex enteric coated tablet, plain on both sides
Sample quantity: 42 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 95 | Medicine: Aspirin | Source: JAUSH | Batch No: ASA31B25 | Exp : Jan.27

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 26/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP-2022	Complies	-	-	-
3	Average weight		102.3	mg	-	-
4	Uniformity of weight		-2.1 to + 1.4	%	-	± 7.5
5	Dissolution					
	A. Acid stage	IP- 2022	3.5 to 6.1	%	75 mg	Not more than 10
	B. Buffer stage		87.3 to 94.1	%		Q. Not less than 70
6	Salicylic acid	IP- 2022	Not detected	%	75 mg	Not more than 3.0
7	Assay: Each enteric coated tablet contains					
	Aspirin	IP- 2022	73.4 mg (i.e. 97.9 %)	mg	75 mg	71.25 mg to 78.75 mg (i.e. 95.0 % to 105.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050328-01
Report date: 28/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02006

Sample name: Ecosprin (Aspirin Gastro-Resistant Tablets IP 150 mg)

Sample appearance: Orange coloured round shaped biconvex Gastro-Resistant tablet, plain on both sides

Sample quantity: 42 Nos

Condition on receipt: Good

Sample packing: Sealed Pack

Environmental condition: Not Applicable

Customer provided details: S.R No : 96 | Medicine: Aspirin | Source: BRAND | Batch No: 56001884 | Exp : Apr.27

Sample receipt date: 12/12/2025

Analysed between: 12/12/2025 to 26/12/2025

Sampling details: Not Sampled by Eureka

Sample seal no.: Not Applicable

Sampling procedure: Not Applicable

Sampling date: Not Applicable

Sampling location: Not Applicable

Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP-2022	Complies	-	-	-
3	Average weight		195.4	mg	-	-
4	Uniformity of weight		-1.6 to + 1.9	%	-	± 5.0
5	Dissolution					
	A. Acid stage	IP- 2022	2.1 to 4.6	%	150 mg	Not more than 10
	B. Buffer stage		87.3 to 94.1	%		Q. Not less than 70
6	Salicylic acid	IP- 2022	Not detected	%	150 mg	Not more than 3.0
7	Assay: Each Gastro-Resistant tablet contains					
	Aspirin	IP- 2022	152.5 mg (i.e. 101.7 %)	mg	150 mg	142.5 mg to 157.5 mg (i.e. 95.0 % to 105.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050329-01
Report date: 28/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02007
Sample name: Calcium and vitamin D3 Tablets IP
Sample appearance: White elongated shaped biconvex film coated tablet, plain on both sides
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 97 | Medicine: Calcium+Vit D | Source: JAUSH | Batch No: 10114 | Exp : May.27

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 26/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		1.464	gm	-	-
4	Uniformity of weight		-1.1 to +1.6	%	-	±5.0
5	Dissolution (For Calcium)		92.7 to 96.6	%	500 mg	Q. Not less than 70
6	Uniformity of content (For Vitamin D3)		95.2 to 103.4	%	250 IU	85.0 to 115.0
7	Assay: Each film coated tablet contains					
	Calcium carbonate Equivalent to Elemental Calcium	IP-2022	494.3 mg (i.e. 98.9 %)	mg	500 mg	450.0 mg to 550.0 mg (i.e. 90.0 % to 110.0 %)
	Cholecalciferol (Vitamin D3)		305.2 (i.e. 122.1 %)	IU	250 IU	Not less than 225 IU (i.e. Not less than 90.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050330-01
Report date: 28/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02008

Sample name: Swasthya calcium (Calcium and vitamin D_3 Tablets IP)

Sample appearance: Blue coloured elongated shaped biconvex film coated tablet, scored on one side and plain on other side

Sample quantity: 45 Nos

Condition on receipt: Good

Sample packing: Sealed Pack

Environmental condition: Not Applicable

Customer provided details: S.R No : 98 | Medicine: Calcium+Vit D | Source: GENADH | Batch No: T2502049 | Exp : Jan.27

Sample receipt date: 12/12/2025

Analysed between: 12/12/2025 to 26/12/2025

Sampling details: Not Sampled by Eureka

Sample seal no.: Not Applicable

Sampling procedure: Not Applicable

Sampling date: Not Applicable

Sampling location: Not Applicable

Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		1.483	gm	-	-
4	Uniformity of weight		-0.8 to +1.2	%	-	±5.0
5	Dissolution (For Calcium)		93.4 to 97.4	%	500 mg	Q. Not less than 70
6	Uniformity of content (For Vitamin D3)		94.3 to 105.9	%	250 IU	85.0 to 115.0
7	Assay: Each film coated tablet contains					
	Calcium carbonate Equivalent to Elemental Calcium	IP-2022	492.8 mg (i.e. 98.6 %)	mg	500 mg	450.0 mg to 550.0 mg (i.e. 90.0 % to 110.0 %)
	Cholecalciferol (Vitamin D3)		299.1 (i.e. 119.6 %)	IU	250 IU	Not less than 225 IU (i.e. Not less than 90.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050331-01
Report date: 28/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02009
Sample name: Calcium and vitamin D3 Tablets IP
Sample appearance: White elongated shaped biconvex film coated tablet, scored on one side and plain on other side
Sample quantity: 30 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 99 | Medicine: Calcium+Vit D | Source: DAVA | Batch No: PM31AK17 | Exp : Oct.26

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 26/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		1.495	gm	-	-
4	Uniformity of weight		-1.3 to +1.1	%	-	±5.0
5	Dissolution (For Calcium)		91.1 to 95.3	%	500 mg	Q. Not less than 70
6	Uniformity of content (For Vitamin D3)		92.4 to 104.7	%	250 IU	85.0 to 115.0
7	Assay: Each film coated tablet contains					
	Calcium carbonate Equivalent to Elemental Calcium	IP-2022	490.7 mg (i.e. 98.1 %)	mg	500 mg	450.0 mg to 550.0 mg (i.e. 90.0 % to 110.0 %)
	Cholecalciferol (Vitamin D3)		310.5 (i.e. 124.2 %)	IU	250 IU	Not less than 225 IU (i.e. Not less than 90.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050332-01
Report date: 28/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02010

Sample name: Eldecal-500 (Calcium and vitamin D_3 Tablets IP)

Sample appearance: White elongated shaped biconvex film coated tablet, plain on both sides

Sample quantity: 45 Nos

Condition on receipt: Good

Sample packing: Sealed Pack

Environmental condition: Not Applicable

Customer provided details: S.R No : 100 | Medicine: Calcium+Vit D | Source: BGENERIC | Batch No: T50311 | Exp : Jun.27

Sample receipt date: 12/12/2025

Analysed between: 12/12/2025 to 26/12/2025

Sampling details: Not Sampled by Eureka

Sample seal no.: Not Applicable

Sampling procedure: Not Applicable

Sampling date: Not Applicable

Sampling location: Not Applicable

Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		1.506	gm	-	-
4	Uniformity of weight		-0.7 to +1.4	%	-	±5.0
5	Dissolution (For Calcium)		95.1 to 102.3	%	500 mg	Q. Not less than 70
6	Uniformity of content (For Vitamin D3)		94.6 to 105.2	%	250 IU	85.0 to 115.0
7	Assay: Each film coated tablet contains					
	Calcium carbonate Equivalent to Elemental Calcium	IP-2022	503.4 mg (i.e. 100.7 %)	mg	500 mg	450.0 mg to 550.0 mg (i.e. 90.0 % to 110.0 %)
	Cholecalciferol (Vitamin D3)		345.4 (i.e. 138.2 %)	IU	250 IU	Not less than 225 IU (i.e. Not less than 90.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050333-01
Report date: 28/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02011

Sample name: Shel D 500 (Calcium and vitamin D3 Tablets IP)

Sample appearance: Light green coloured elongated shaped biconvex film coated tablet, plain on both sides

Sample quantity: 45 Nos

Condition on receipt: Good

Sample packing: Sealed Pack

Environmental condition: Not Applicable

Customer provided details: S.R No : 101 | Medicine: Calcium+Vit D | Source: BGENERIC | Batch No: THT-250769 | Exp : Jan.27

Sample receipt date: 12/12/2025

Analysed between: 12/12/2025 to 26/12/2025

Sampling details: Not Sampled by Eureka

Sample seal no.: Not Applicable

Sampling procedure: Not Applicable

Sampling date: Not Applicable

Sampling location: Not Applicable

Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		1.522	gm	-	-
4	Uniformity of weight		-0.6 to +1.3	%	-	±5.0
5	Dissolution (For Calcium)		96.3 to 101.5	%	500 mg	Q. Not less than 70
6	Uniformity of content (For Vitamin D3)		96.9 to 105.1	%	250 IU	85.0 to 115.0
7	Assay: Each film coated tablet contains					
	Calcium carbonate Equivalent to Elemental Calcium	IP-2022	503.7 mg (i.e. 100.7 %)	mg	500 mg	450.0 mg to 550.0 mg (i.e. 90.0 % to 110.0 %)
	Cholecalciferol (Vitamin D3)		330.9 (i.e. 132.4 %)	IU	250 IU	Not less than 225 IU (i.e. Not less than 90.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050334-01
Report date: 28/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02012

Sample name: Cipcal-500 (Calcium and vitamin D_3 Tablets IP)

Sample appearance: White elongated shaped biconvex film coated tablet, plain on both sides

Sample quantity: 45 Nos

Condition on receipt: Good

Sample packing: Sealed Pack

Environmental condition: Not Applicable

Customer provided details: S.R No : 102 | Medicine: Calcium+Vit D | Source: BRAND | Batch No: AMQ365AJA | Exp : Mar.28

Sample receipt date: 12/12/2025

Analysed between: 12/12/2025 to 26/12/2025

Sampling details: Not Sampled by Eureka

Sample seal no.: Not Applicable

Sampling procedure: Not Applicable

Sampling date: Not Applicable

Sampling location: Not Applicable

Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		1.501	gm	-	-
4	Uniformity of weight		-1.2 to +0.6	%	-	±5.0
5	Dissolution (For Calcium)		97.3 to 103.2	%	500 mg	Q. Not less than 70
6	Uniformity of content (For Vitamin D3)		95.7 to 104.8	%	250 IU	85.0 to 115.0
7	Assay: Each film coated tablet contains					
	Calcium carbonate Equivalent to Elemental Calcium	IP-2022	507.1 mg (i.e. 101.4 %)	mg	500 mg	450.0 mg to 550.0 mg (i.e. 90.0 % to 110.0 %)
	Cholecalciferol (Vitamin D3)		355.9 (i.e. 142.4 %)	IU	250 IU	Not less than 225 IU (i.e. Not less than 90.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH), Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02013

Sample name: SHELCAL500 (Calcium and vitamin D_3 Tablets IP)

Sample appearance: Light green coloured elongated shaped biconvex film coated tablet, plain on both sides

Sample quantity: 45 Nos

Condition on receipt: Good

Sample packing: Sealed Pack

Environmental condition: Not Applicable

Customer provided details: S.R No : 103 | Medicine: Calcium+Vit D | Source: BRAND | Batch No: 8LV2M203 | Exp : Apr.27

Sample receipt date: 12/12/2025

Analysed between: 12/12/2025 to 26/12/2025

Sampling details: Not Sampled by Eureka

Sample seal no.: Not Applicable

Sampling procedure: Not Applicable

Sampling date: Not Applicable

Sampling location: Not Applicable

Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		1.519	gm	-	-
4	Uniformity of weight		-1.4 to +0.8	%	-	±5.0
5	Dissolution (For Calcium)		95.8 to 102.5	%	500 mg	Q. Not less than 70
6	Uniformity of content (For Vitamin D3)		96.3 to 102.9	%	250 IU	85.0 to 115.0
7	Assay: Each film coated tablet contains					
	Calcium carbonate Equivalent to Elemental Calcium	IP-2022	507.6 mg (i.e. 101.5 %)	mg	500 mg	450.0 mg to 550.0 mg (i.e. 90.0 to 110.0 %)
	Cholecalciferol (Vitamin D3)		348.7 (i.e. 139.5 %)	IU	250 IU	Not less than 225 IU (i.e. Not less than 90.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050175-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02014
Sample name: Folic acid Tablets IP 5 mg
Sample appearance: Yellow coloured round shaped flat uncoated tablet, scored on one side and plain on other side
Sample quantity: 45 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 104 | Medicine: Folic Acid | Source: JAUSH | Batch No: FAT1302 | Exp : Mar.27

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 19/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		122.8	mg	-	-
4	Dissolution		92.3 to 97.8	%	5 mg	Q. Not less than 75
5	Hydrolysis products		Complies	-		-
6	Uniformity of content		95.6 to 101.9	%		85.0 to 115.0
7	Assay: Each uncoated tablet contains					
	Folic acid	IP-2022	5.12 mg (i.e. 102.4 %)	mg	5 mg	4.50 mg to 5.75 mg (i.e. 90.0 % to 115.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050176-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02015
Sample name: Folic acid Tablets IP 5 mg
Sample appearance: Yellow coloured round shaped flat uncoated tablet, scored on one side and plain on other side
Sample quantity: 45 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 105 | Medicine: Folic Acid | Source: DAVA | Batch No: T-240926 | Exp : Nov.26

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 19/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		106.7	mg	-	-
4	Dissolution		96.3 to 102.6	%	5 mg	Q. Not less than 75
5	Hydrolysis products		Complies	-		-
6	Uniformity of content		95.5 to 103.5	%		85.0 to 115.0
7	Assay: Each uncoated tablet contains					
	Folic acid	IP-2022	5.15 mg (i.e. 103.0 %)	mg	5 mg	4.50 mg to 5.75 mg (i.e. 90.0 % to 115.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050177-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02016
Sample name: Folic acid Tablets IP 5 mg
Sample appearance: Yellow coloured round shaped flat uncoated tablet, scored on one side and plain on other side
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 19/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

Customer provided details: S.R No : 106 | Medicine: Folic Acid | Source: BGENERIC | Batch No: T-2507019 | Exp : Jun.27

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		78.1	mg	-	-
4	Dissolution		96.9 to 103.2	%	5 mg	Q. Not less than 75
5	Hydrolysis products		Complies	-		-
6	Uniformity of content		96.9 to 102.7	%		85.0 to 115.0
7	Assay: Each uncoated tablet contains					
	Folic acid	IP-2022	10.29 mg (i.e. 102.9 %)	mg	5 mg	4.50 mg to 5.75 mg (i.e. 90.0 % to 115.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050178-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02017
Sample name: Folic acid Tablets IP 5 mg
Sample appearance: Yellow coloured round shaped flat uncoated tablet, scored on one side and plain on other side
Sample quantity: 45 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 107 | Medicine: Folic Acid | Source: BRAND | Batch No: MP6289 | Exp : Nov.26

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 19/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		71.2	mg	-	-
4	Dissolution		94.9 to 102.8	%	5 mg	Q. Not less than 75
5	Hydrolysis products		Complies	-		-
6	Uniformity of content		96.8 to 102.5	%		85.0 to 115.0
7	Assay: Each uncoated tablet contains					
	Folic acid	IP-2022	5.18 mg (i.e. 103.6 %)	mg	5 mg	4.50 mg to 5.75 mg (i.e. 90.0 % to 115.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050179-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02018
Sample name: Folic acid Tablets IP 5 mg
Sample appearance: Yellow coloured round shaped flat uncoated tablet, scored on one side and having a logo on other side
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 108 | Medicine: Folic Acid | Source: BRAND | Batch No: HSL030425 | Exp : Mar.27

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 19/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		92.5	mg	-	-
4	Dissolution		98.5 to 103.9	%	5 mg	Q. Not less than 75
5	Hydrolysis products		Complies	-		-
6	Uniformity of content		96.8 to 102.7	%		85.0 to 115.0
7	Assay: Each uncoated tablet contains					
	Folic acid	IP-2022	10.19 mg (i.e. 101.9 %)	mg	5 mg	4.50 mg to 5.75 mg (i.e. 90.0 % to 115.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050180-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02019
Sample name: Prednisolone Tablets IP 10 mg
Sample appearance: White round shaped flat uncoated tablet, scored on one side and plain on other side
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 109 | Medicine: Prednisolone | Source: JAUSH | Batch No: PRDT-1031 | Exp : Dec.26

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 23/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		200.5	mg	-	-
4	Dissolution		86.5 to 93.5	%	10 mg	Q. Not less than 70
5	Uniformity of content		96.6 to 103.3	%		85.0 to 115.0
6	Related substances					
	Any secondary Impurity	IP-2022	Not detected	%	10 mg	Not more than 1.0
	Sum of all the secondary Impurities		Not detected	%		Not more than 3.0
7	Assay: Each uncoated tablet contains					
	Prednisolone	IP-2022	9.78 mg (i.e. 97.8 %)	mg	10 mg	9.0 mg to 11.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050181-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02020
Sample name: RACECORT-10 (Prednisolone Tablets IP 10 mg)
Sample appearance: White round shaped flat uncoated tablet, scored on one side and plain on other side
Sample quantity: 45 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 110 | Medicine: Prednisolone | Source: GENERIC | Batch No: GT-188 | Exp : Mar.27

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 23/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		101.2	mg	-	-
4	Dissolution		93.3 to 102.6	%	10 mg	Q. Not less than 70
5	Uniformity of content		94.2 to 102.7	%		85.0 to 115.0
6	Related substances					
	Any secondary Impurity	IP-2022	Not detected	%	10 mg	Not more than 1.0
	Sum of all the secondary Impurities		Not detected	%		Not more than 3.0
7	Assay: Each uncoated tablet contains					
	Prednisolone	IP-2022	9.63 mg (i.e. 96.3 %)	mg	10 mg	9.0 mg to 11.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050182-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02021
Sample name: Beslone 10 (Prednisolone Tablets IP 10 mg)
Sample appearance: White round shaped flat uncoated tablet, scored on one side and plain on other side
Sample quantity: 60 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 111 | Medicine: Prednisolone | Source: BGENERIC| Batch No: BLT-2404 | Exp : May.27

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 23/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		150.2	mg	-	-
4	Dissolution		93.8 to 101.8	%	10 mg	Q. Not less than 70
5	Uniformity of content		95.8 to 101.7	%		85.0 to 115.0
6	Related substances					
	Any secondary Impurity	IP-2022	Not detected	%	10 mg	Not more than 1.0
	Sum of all the secondary Impurities		Not detected	%		Not more than 3.0
7	Assay: Each uncoated tablet contains					
	Prednisolone	IP-2022	10.12 mg (i.e. 101.2 %)	mg	10 mg	9.0 mg to 11.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050183-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02022

Sample name: Wysolone 10 (Prednisolone dispersible Tablets 10 mg)

Sample appearance: White round shaped flat uncoated dispersible tablet, scored on one side and inscribed "10" on other side

Sample quantity: 45 Nos

Condition on receipt: Good

Sample packing: Sealed Pack

Environmental condition: Not Applicable

Customer provided details: S.R No : 112 | Medicine: Prednisolone | Source: BRAND | Batch No: MR5736 | Exp : May.27

Sample receipt date: 12/12/2025

Analysed between: 12/12/2025 to 23/12/2025

Sampling details: Not Sampled by Eureka

Sample seal no.: Not Applicable

Sampling procedure: Not Applicable

Sampling date: Not Applicable

Sampling location: Not Applicable

Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	In house specification	Positive of prednisolone	-	-	-
3	Average weight		110.3	mg	-	-
4	Uniformity of dispersion		Passes the test	-	-	-
5	Disintegration time		40 sec to 45 sec	minutes	-	Not more than 3
6	Uniformity of content		95.8 to 102.4	%	10 mg	85.0 to 115.0
7	Assay: Each uncoated dispersible tablet contains					
	Prednisolone	In house specification	10.15 mg (i.e. 101.5 %)	mg	10 mg	9.0 mg to 11.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050184-01
Report date: 27/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02023
Sample name: Omnacortil-10 (Prednisolone dispersible Tablets 10 mg)
Sample appearance: White round shaped biconvex uncoated dispersible tablet, inscribed “O 10” on score side and plain on other side
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 113 | Medicine: Prednisolone | Source: BRAND | Batch No: 13251010A | Exp : May.29

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 23/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	In house specification	Positive of prednisolone	-	-	-
3	Average weight		104.8	mg	-	-
4	Uniformity of dispersion		Passes the test	-	-	-
5	Disintegration time		30 sec to 35 sec	minutes	-	Not more than 3
6	Uniformity of content		96.3 to 101.9	%	10 mg	85.0 to 115.0
7	Assay: Each uncoated dispersible tablet contains					
	Prednisolone	In house specification	10.23 mg (i.e. 102.3 %)	mg	10 mg	9.0 mg to 11.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050336-01
Report date: 28/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02024
Sample name: Ursodeoxycholic Acid Tablets IP 300 mg
Sample appearance: White elongated shaped biconvex film coated tablet, plain on both sides
Sample quantity:50 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 114 | Medicine: UDCA | Source: JAUSH | Batch No: BPUR24002 | Exp : Apr.26

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 27/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		614.4	mg	-	-
4	Uniformity of weight		-1.7 to + 2.1	%	-	± 5.0
5	Dissolution		85.3 to 92.7	%	300 mg	Q. Not less than 75
6	Related substances		Complies	-		-
7	Assay: Each film coated tablet contains					
	Ursodeoxycholic Acid	IP- 2022	294.2 mg (i.e. 98.1 %)	mg	300 mg	277.5 mg to 322.5 mg (i.e. 92.5 % to 107.5 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050337-01
Report date: 28/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02025
Sample name: Ursodeoxycholic Acid Tablets IP 300 mg
Sample appearance: Yellow coloured round shaped biconvex film coated tablet, plain on both sides
Sample quantity: 45 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 115 | Medicine: UDCA | Source: GENADH | Batch No: 169BT11 | Exp : May.27

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 27/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		354.4	mg	-	-
4	Uniformity of weight		-1.9 to + 1.4	%	-	± 5.0
5	Dissolution		86.7 to 93.9	%	300 mg	Q. Not less than 75
6	Related substances		Complies	-		-
7	Assay: Each film coated tablet contains					
	Ursodeoxycholic Acid	IP- 2022	292.4 mg (i.e. 97.5 %)	mg	300 mg	277.5 mg to 322.5 mg (i.e. 92.5 % to 107.5 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050338-01
Report date: 28/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02026
Sample name: Ursodeoxycholic Acid Tablets IP 300 mg
Sample appearance: Orange coloured round shaped biconvex uncoated tablet, plain on both sides
Sample quantity: 50 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 116 | Medicine: UDCA | Source: DAVA | Batch No: IA225013 | Exp : Jul.27

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 27/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		372.2	mg	-	-
4	Uniformity of weight		-1.4 to + 1.2	%	-	± 5.0
5	Dissolution		84.6 to 90.1	%	300 mg	Q. Not less than 75
6	Related substances		Complies	-		-
7	Assay: Each uncoated tablet contains					
	Ursodeoxycholic Acid	IP- 2022	287.3 mg (i.e. 95.8 %)	mg	300 mg	277.5 mg to 322.5 mg (i.e. 92.5 % to 107.5 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050339-01
Report date: 28/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH), Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02027

Sample name: Udicyte 300 (Ursodeoxycholic Acid Tablets IP 300 mg)

Sample appearance: White elongated shaped biconvex uncoated tablet, plain on both sides

Sample quantity: 45 Nos

Condition on receipt: Good

Sample packing: Sealed Pack

Environmental condition: Not Applicable

Customer provided details: S.R No : 117 | Medicine: UDCA | Source: BGENERIC | Batch No: I25003 | Exp : May.27

Sample receipt date: 12/12/2025

Analysed between: 12/12/2025 to 27/12/2025

Sampling details: Not Sampled by Eureka

Sample seal no.: Not Applicable

Sampling procedure: Not Applicable

Sampling date: Not Applicable

Sampling location: Not Applicable

Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		405.4	mg	-	-
4	Uniformity of weight		-1.4 to + 0.8	%	-	± 5.0
5	Dissolution		93.4 to 99.6	%	300 mg	Q. Not less than 75
6	Related substances		Complies	-		-
7	Assay: Each uncoated tablet contains					
	Ursodeoxycholic Acid	IP- 2022	302.3 mg (i.e. 100.8 %)	mg	300 mg	277.5 mg to 322.5 mg (i.e. 92.5 % to 107.5 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050340-01
Report date: 28/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02028

Sample name: Usibon-300 (Ursodeoxycholic Acid Tablets IP 300 mg)

Sample appearance: White round shaped biconvex film coated tablet, scored on one side and plain on other side

Sample quantity: 40 Nos

Condition on receipt: Good

Sample packing: Sealed Pack

Environmental condition: Not Applicable

Customer provided details: S.R No : 118 | Medicine: UDCA | Source: BGENERIC | Batch No: USBS0063 | Exp : Jul.27

Sample receipt date: 12/12/2025

Analysed between: 12/12/2025 to 27/12/2025

Sampling details: Not Sampled by Eureka

Sample seal no.: Not Applicable

Sampling procedure: Not Applicable

Sampling date: Not Applicable

Sampling location: Not Applicable

Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		512.2	mg	-	-
4	Uniformity of weight		-0.6 to + 1.3	%	-	± 5.0
5	Dissolution		96.4 to 101.4	%	300 mg	Q. Not less than 75
6	Related substances		Complies	-		-
7	Assay: Each film coated tablet contains					
	Ursodeoxycholic Acid	IP- 2022	304.1 mg (i.e. 101.4 %)	mg	300 mg	277.5 mg to 322.5 mg (i.e. 92.5 % to 107.5 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02029

Sample name: Udiliv 300 (Ursodeoxycholic Acid Tablets IP 300 mg)

Sample appearance: White elongated shaped biconvex uncoated tablet, having inscribed “UDL 300” on one side and scored on other side

Sample quantity: 40 Nos

Condition on receipt: Good

Sample packing: Sealed Pack

Environmental condition: Not Applicable

Customer provided details: S.R No : 119 | Medicine: UDCA | Source: BRAND | Batch No: 792921D7 | Exp : Jun.28

Sample receipt date: 12/12/2025

Analysed between: 12/12/2025 to 27/12/2025

Sampling details: Not Sampled by Eureka

Sample seal no.: Not Applicable

Sampling procedure: Not Applicable

Sampling date: Not Applicable

Sampling location: Not Applicable

Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		366.6	mg	-	-
4	Uniformity of weight		-2.1 to + 1.8	%	-	± 5.0
5	Dissolution		94.7 to 101.9	%	300 mg	Q. Not less than 75
6	Related substances		Complies	-		-
7	Assay: Each uncoated tablet contains					
	Ursodeoxycholic Acid	IP- 2022	303.2 mg (i.e. 101.1 %)	mg	300 mg	277.5 mg to 322.5 mg (i.e. 92.5 % to 107.5 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050342-01
Report date: 28/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02030
Sample name: Ursocol 300 (Ursodeoxycholic Acid Tablets IP)
Sample appearance: Maroon coloured round shaped biconvex film coated tablet, scored on one side and plain on other side
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 120 | Medicine: UDCA | Source: BRAND | Batch No: GTG1994A | Exp : Jun.27

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 27/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification (A & B)	IP-2022	Complies	-	-	-
3	Average weight		565.5	mg	-	-
4	Uniformity of weight		-1.1 to + 1.5	%	-	± 5.0
5	Dissolution		96.1 to 101.7	%	300 mg	Q. Not less than 75
6	Related substances		Complies	-		-
7	Assay: Each film coated tablet contains					
	Ursodeoxycholic Acid	IP- 2022	302.7 mg (i.e. 100.9 %)	mg	300 mg	277.5 mg to 322.5 mg (i.e. 92.5 % to 107.5 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050343-01
Report date: 28/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02031
Sample name: Rifaximin Tablets IP 400 mg
Sample appearance: Orange coloured elongated shaped biconvex film coated tablet, scored on one side and plain on other side
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 121 | Medicine: Rifaximin | Source: DAVA | Batch No: LGN09/049/02 | Exp : Aug.26

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 25/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP Addendum 2024	Complies	-	-	-
3	Average weight		784.3	mg	-	-
4	Uniformity of weight		-0.7 to +0.9	%	-	± 5.0
5	Dissolution		93.6 to 97.8	%	400 mg	Q. Not less than 70
6	Related substances					
	Impurity D	IP Addendum 2024	Not detected	%	400 mg	Not more than 0.5
	Impurity H		Not detected	%		Not more than 0.5
	Any other secondary impurity		Not detected	%		Not more than 0.2
	Sum of all the secondary impurities		Not detected	%		Not more than 1.5
7	Assay: Each film coated tablet contains					

	Rifaximin	IP Addendum 2024	390.7 mg (i.e. 97.7 %)	mg	400 mg	380.0 mg to 420.0 mg (i.e. 95.0 % to 105.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050344-01
Report date: 28/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02032
Sample name: RIFAXIT-400 (Rifaximin Tablets 400 mg)
Sample appearance: Orange coloured elongated shaped biconvex film coated tablet, scored on one side and plain on other side
Sample quantity: 45 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 25/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

Customer provided details: S.R No : 122 | Medicine: Rifaximin | Source: GENERIC | Batch No: T241570 | Exp : Aug.26

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP Addendum 2024	Complies	-	-	-
3	Average weight		690.3	mg	-	-
4	Uniformity of weight		-1.1 to + 0.8	%	-	± 5.0
5	Dissolution		94.8 to 99.2	%	400 mg	Q. Not less than 70
6	Related substances					
	Impurity D	IP Addendum 2024	Not detected	%	400 mg	Not more than 0.5
	Impurity H		Not detected	%		Not more than 0.5
	Any other secondary impurity		Not detected	%		Not more than 0.2
	Sum of all the secondary impurities		Not detected	%		Not more than 1.5
7	Assay: Each film coated tablet contains					

	Rifaximin	IP Addendum 2024	395.4 mg (i.e. 98.9 %)	mg	400 mg	380.0 mg to 420.0 mg (i.e. 95.0 % to 105.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050345-01
Report date: 28/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02033
Sample name: Rifagut-400 (Rifaximin Tablets IP)
Sample appearance: Light orange coloured elongated shaped biconvex film coated tablet, plain on both sides
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 123 | Medicine: Rifaximin | Source: BRAND | Batch No: GKG1011A | Exp : May.27

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 25/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP Addendum 2024	Complies	-	-	-
3	Average weight		743.3	mg	-	-
4	Uniformity of weight		-1.3 to + 1.1	%	-	± 5.0
5	Dissolution		96.6 to 102.7	%	400 mg	Q. Not less than 70
6	Related substances					
	Impurity D	IP Addendum 2024	Not detected	%	400 mg	Not more than 0.5
	Impurity H		Not detected	%		Not more than 0.5
	Any other secondary impurity		Not detected	%		Not more than 0.2
	Sum of all the secondary impurities		Not detected	%		Not more than 1.5
7	Assay: Each film coated tablet contains					

	Rifaximin	IP Addendum 2024	403.7 mg (i.e. 100.9 %)	mg	400 mg	380.0 mg to 420.0 mg (i.e. 95.0 % to 105.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050346-01
Report date: 28/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02034

Sample name: Rifasan (Rifaximin Tablets IP 400 mg)

Sample appearance: Light yellow coloured elongated shaped biconvex film coated tablet, scored on one side and plain on other side

Sample quantity: 40 Nos

Condition on receipt: Good

Sample packing: Sealed Pack

Environmental condition: Not Applicable

Customer provided details: S.R No : 124 | Medicine: Rifaximin | Source: BRAND | Batch No: ART-505 | Exp : Jul.27

Sample receipt date: 12/12/2025

Analysed between: 12/12/2025 to 25/12/2025

Sampling details: Not Sampled by Eureka

Sample seal no.: Not Applicable

Sampling procedure: Not Applicable

Sampling date: Not Applicable

Sampling location: Not Applicable

Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Unit	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	IP Addendum 2024	Complies	-	-	-
3	Average weight		750.6	mg	-	-
4	Uniformity of weight		-1.3 to + 0.8	%	-	± 5.0
5	Dissolution		97.4 to 103.6	%	400 mg	Q. Not less than 70
6	Related substances					
	Impurity D	IP Addendum 2024	Not detected	%	400 mg	Not more than 0.5
	Impurity H		Not detected	%		Not more than 0.5
	Any other secondary impurity		Not detected	%		Not more than 0.2
	Sum of all the secondary impurities		Not detected	%		Not more than 1.5
7	Assay: Each film coated tablet contains					

	Rifaximin	IP Addendum 2024	402.8 mg (i.e. 100.7 %)	mg	400 mg	380.0 mg to 420.0 mg (i.e. 95.0 % to 105.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050347-01
Report date: 28/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02035
Sample name: Febuxostat Tablets 40 mg
Sample appearance: White round shaped biconvex film coated tablet, plain on both sides
Sample quantity: 50 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 125 | Medicine: Febuxostat | Source: JAUSH | Batch No: BRE06207A | Exp : May.28

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 27/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	In house specification	Positive for Febuxostat	-	-	-
3	Average weight		254.1	mg	-	-
4	Uniformity of weight		-1.1 to +1.2	%	-	±5.0
5	Disintegration time		6 to 7	minutes	-	Not more than 30
6	Assay: Each film coated tablet contains					
	Febuxostat	In house specification	38.3 mg (i.e. 95.8 %)	mg	40 mg	36.0 mg to 44.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Eureka Analytical Services Private Limited
31st Milestone, Main GT Road, Near AMR Mall, Kundli, Sonipat, Haryana- 131028, India.
Email: info@eurekaserv.com, Website: www.eurekaserv.com, CIN: U73100KA2019PTC127732

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050348-01
Report date: 28/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02036
Sample name: Febuswas-40 (Febuxostat Tablets 40 mg)
Sample appearance: Yellow coloured round shaped biconvex film coated tablet, plain on both sides
Sample quantity: 45 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 126 | Medicine: Febuxostat | Source: GENADH | Batch No: AGT50231 | Exp : Jan.27

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 27/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	In house specification	Positive for Febuxostat	-	-	-
3	Average weight		170.6	mg	-	-
4	Uniformity of weight		-1.7 to +2.2	%	-	±7.5
5	Disintegration time		8 to 9	minutes	-	Not more than 30
6	Assay: Each film coated tablet contains					
	Febuxostat	In house specification	38.7 mg (i.e. 96.8 %)	mg	40 mg	36.0 mg to 44.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050349-01
Report date: 28/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02037
Sample name: Febuxostat Tablets 40 mg
Sample appearance: Orange coloured round shaped biconvex film coated tablet, plain on both sides
Sample quantity: 50 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 127 | Medicine: Febuxostat | Source: DAVA | Batch No: FXH25004 | Exp : Jan.27

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 27/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	In house specification	Positive for Febuxostat	-	-	-
3	Average weight		167.1	mg	-	-
4	Uniformity of weight		-1.5 to +1.9	%	-	±7.5
5	Disintegration time		8 to 9	minutes	-	Not more than 30
6	Assay: Each film coated tablet contains					
	Febuxostat	In house specification	38.9 mg (i.e. 97.3 %)	mg	40 mg	36.0 mg to 44.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050350-01
Report date: 28/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02038
Sample name: Febuwal-40 (Febuxostat Tablets)
Sample appearance: White round shaped biconvex film coated tablet, plain on both sides
Sample quantity: 50 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 128 | Medicine: Febuxostat | Source: BGENERIC | Batch No: AGQ02BMA | Exp : May.27

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 27/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	In house specification	Positive for Febuxostat	-	-	-
3	Average weight		152.9	mg	-	-
4	Uniformity of weight		-1.8 to +1.1	%	-	±7.5
5	Disintegration time		5 to 6	minutes	-	Not more than 30
6	Assay: Each film coated tablet contains					
	Febuxostat	In house specification	39.3 mg (i.e. 98.3 %)	mg	40 mg	36.0 mg to 44.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Eureka Analytical Services Private Limited
31st Milestone, Main GT Road, Near AMR Mall, Kundli, Sonipat, Haryana- 131028, India.
Email: info@eurekaserv.com, Website: www.eurekaserv.com, CIN: U73100KA2019PTC127732

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050351-01
Report date: 28/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02039
Sample name: Uristat 40 (Febuxostat Tablets 40 mg)
Sample appearance: Orange coloured round shaped biconvex film coated tablet, plain on both sides
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 129 | Medicine: Febuxostat | Source: BGENERIC | Batch No: DT3475B | Exp : Apr.27

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 27/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	In house specification	Positive for Febuxostat	-	-	-
3	Average weight		146.1	mg	-	-
4	Uniformity of weight		-1.3 to +1.1	%	-	±7.5
5	Disintegration time		7 to 8	minutes	-	Not more than 30
6	Assay: Each film coated tablet contains					
	Febuxostat	In house specification	39.5 mg (i.e. 98.8 %)	mg	40 mg	36.0 mg to 44.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050352-01
Report date: 28/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02040
Sample name: Febutaz-40 (Febuxostat Tablets)
Sample appearance: Orange coloured round shaped biconvex film coated tablet, scored on one side and plain on other side
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 130 | Medicine: Febuxostat | Source: BRAND | Batch No: SIG1673A | Exp : Jan.28

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 27/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	In house specification	Positive for Febuxostat	-	-	-
3	Average weight		124.8	mg	-	-
4	Uniformity of weight		-1.6 to +1.0	%	-	±7.5
5	Disintegration time		5 to 6	minutes	-	Not more than 30
6	Assay: Each film coated tablet contains					
	Febuxostat	In house specification	40.4 mg (i.e. 101.0 %)	mg	40 mg	36.0 mg to 44.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********

EUREKA

Member of GBAGROUP

Report code: TR-25-EKA2-050353-01
Report date: 28/12/2025

Citizens Generic Vs Branded Drugs Project

Mission for Ethics and Science in Healthcare (MESH),
Gowrisankaram, PRA 93B Pattoor, Pettah, 695024

Scan for Authentication

ANALYTICAL REPORT

Sample code: EKA2-25-12-02041
Sample name: Feburic 40 (Febuxostat Tablets 40 mg)
Sample appearance: White round shaped biconvex film coated tablet, scored on one side and plain on other side
Sample quantity: 40 Nos
Condition on receipt: Good
Sample packing: Sealed Pack
Environmental condition: Not Applicable
Customer provided details: S.R No : 131 | Medicine: Febuxostat | Source: BRAND | Batch No: GT16155 | Exp : Jul.28

Sample receipt date: 12/12/2025
Analysed between: 12/12/2025 to 27/12/2025
Sampling details: Not Sampled by Eureka
Sample seal no.: Not Applicable
Sampling procedure: Not Applicable
Sampling date: Not Applicable
Sampling location: Not Applicable
Job file no.: Not Applicable

TEST RESULTS

Sr. No	Test Parameter	Test Method	Result	Units	Label Claim	Limit
CHEMICAL						
1	Description	-	Complies	-	-	-
2	Identification	In house specification	Positive for Febuxostat	-	-	-
3	Average weight		101.9	mg	-	-
4	Uniformity of weight		-1.7 to +1.4	%	-	±7.5
5	Disintegration time		6 to 7	minutes	-	Not more than 30
6	Assay: Each film coated tablet contains					
	Febuxostat	In house specification	40.6 mg (i.e. 101.5 %)	mg	40 mg	36.0 mg to 44.0 mg (i.e. 90.0 % to 110.0 %)

Remark: All parameters are complies as per Indian pharmacopoeia specification.

Eureka Analytical Services Private Limited
31st Milestone, Main GT Road, Near AMR Mall, Kundli, Sonipat, Haryana- 131028, India.
Email: info@eurekaserv.com, Website: www.eurekaserv.com, CIN: U73100KA2019PTC127732

Mr. Mohit Tyagi
Deputy Manager
Authorised Signatory

*********End of Report********